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Abstract 
In vitro fertilization (IVF) is used to help infertile couples achieve a live birth.  Clinical 
studies have suggested that multiple, consecutive cycles of IVF can increase live birth 
rate significantly.  Others have documented improved live birth rates from the use of new 
laboratory techniques for preimplantation genetic screening (PGS).  This genetic 
screening technique seeks to determine the ploidy of the embryo prior to implantation 
into the woman.  To date, no study has examined the cost-effectiveness of using IVF in 
conjunction with PGS compared to that of IVF alone for 3 consecutive cycles in 
achieving a live birth.  This study compared the incremental cost-effectiveness ratios 
(ICER) from each intervention arm based on the clinical probabilities for each outcome 
and this study was grounded in the protection motivation theory.  Costs were obtained 
from secondary sources, such as the literature and government databases.  The model was 
constructed using a decision-analytical approach that allowed for z test statistical analysis 
of the outcomes, where the ICER is the dependent variable and the independent variables 
are the 2 interventions.  The robustness of the model was tested through univariate and 
probabilistic sensitivity analysis and stratified by age groups. The results showed that 
PGS with IVF was cost-effective for women aged under 40 and women aged 40-42, but 
not for women over 42.  Based on a willingness-to-pay threshold of $100,000, IVF with 
PGS was the most cost-effective strategy in all age groups. The positive social change 
implication of this study is such that understanding the costs associated with a new 
technology to achieve a live birth is significant for society to help guide clinical treatment 
of these patients.     
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Chapter 1: Introduction to the Study 
In vitro fertilization (IVF) is an assisted reproductive technology (ART) technique 
used by reproductive endocrinologists to help infertile couples conceive (Society for 
Assisted Reproductive Technologies, 2014).  However, for most Americans, IVF is 
extremely expensive, and can cost on average $12,500 per IVF cycle, not including drug 
costs (American Society for Reproductive Medicine, 2014).  The 2012 national average 
live birth rate (Singleton or more) per embryo transfer in the United States is 46.9% for 
women aged under 35, 37.8% for women aged 35 to 37, 28.4% for women aged 38 to 40, 
and less than 16.1% for women 41 and older (National Center for Chronic Disease 
Prevention and Health Promotion, 2014).  Cumulatively, live birth rates increase with 
each IVF attempt, but each cycle is costly and success can vary depending on diagnosis 
of infertility.  Because of costs and other factors, however, drop-out rates before the third 
cycle of IVF have been reported between 17% and 65% (Luke et al., 2012). 
Preimplantation genetic screening (PGS) is a genetic technique used to analyze 
the complement of chromosomes from an individual embryo and determine if it is normal 
(euploid) or abnormal (aneuploid). This type of screening is now typically done using 
array comparative genomic hybridization (aCGH) and has been shown to greatly increase 
pregnancy rates and live birth rates, depending on the age of the participant (Hodes-
Wertz, Grifo, Ghadir, Kaplan, & Laskin, 2012; Yang et al., 2012).  The use of PGS in 
clinical care is controversial, and no clear recent consensus is available for patients or 
clinicians on when and where to use PGS in conjunction with IVF (Brezina & Kutteh, 
2015).    
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Background of Problem 
PGS is a tool that reproductive endocrinologists have been employing in recent 
years to select the best embryos for implantation during IVF cycles.  PGS can be 
performed in a variety of ways, including Array Comparative Genomic Hybridization 
(aCGH) (Handyside, 2013).  PGS involves looking for aneuploidy, or an abnormal 
number of chromosomes in the embryo, prior to implantation in the IVF cycle.  The aim 
of PGS is to decrease miscarriage rates and increase live birth rates (Harper et al., 2012).   
Microarray, or aCGH, is a tool that has been used to determine the etiology of 
products of conception for some time (Ford & Schust, 2009).  Related to that, it has been 
established that roughly 50% of all miscarriages from women with recurrent pregnancy 
loss (RPL) are due to a chromosomal abnormality as detected by aCGH (Ford & Schust, 
2009; Foyouzi, Cedars, & Huddlest, 2012).  Researchers have speculated about the use of 
aCGH as a method to detect these chromosomal abnormalities in embryos prior to 
implantation in an IVF cycle in order to improve pregnancy rates and decrease 
miscarriage rates (Harper et al., 2012).  Next generation sequencing (NGS) is a relatively 
new technique to perform ploidy analysis as well, but researchers have shown it to be just 
as effective at screening for euploid embryos as aCGH (Yang et al., 2015).  Together, 
aCGH and NGS technologies represent PGS 2.0 or PGS #2, distinguishing them from 
prior techniques (Gleicher, Kushnir, & Barad, 2014).  However, guidelines from 
professional societies that govern the use of PGS have stated that no evidence exists that 
the use of PGS increases the live-birth rate for women with RPL (American Society for 
Reproductive Medicine, 2008; Harper & SenGupta, 2012).   
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Researchers have performed multiple randomized control trials (RCTs) to 
understand the connection between PGS and implantation rates.  Three studies 
underscore the current understanding of the use of PGS by CGH and implantation rates 
and miscarriage rates. The first, performed by Yang et al. (2012), was a pilot study of 
young, good prognosis patients.  The results were that the pregnancy rate of the group 
that underwent PGS by CGH achieved a 69.1% pregnancy rate, compared to the control 
group at 41.7% (Yang et al., 2012). However, this study did not specifically look at 
women with RPL, nor did it look at live-birth rates.   
A more recent study by Keltz (2013) looked at a number of patients that had PGS 
by CGH and compared them to a control group without PGS.  This study looked at 
implantation rates, ongoing pregnancy rates, miscarriage rates, and multiple rates.  The 
results were that the PGS group had implantation rates double that of the control group, 
and significantly decreased miscarriage and multiple rates (Keltz, 2013).  However, this 
study did not focus specifically on women with RPL nor did it observe live-birth rates.   
Lastly, the most recent analysis of CGH in PGS does look at RPL.  Hodes-Wertz 
et al. (2012), looked at 2,282 embryos from couples with RPL and analyzed them through 
CGH.  35% were euploid (normal) and 60% were aneuploid.  In 181 transfer cycles, the 
miscarriage rate was 6.9% compared to 33.5% in an RPL control population and 23.7% 
in a general infertile population.  The researchers demonstrated a significant benefit to 
PGS in RPL couple for miscarriages, but did not look at live-birth rates (Hodes-Wertz et 
al., 2012).   
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Other methods for determining the best method for achieving a live birth include 
expectant management, or simply allowing a couple women with RPL to have a natural 
birth without IVF.  Limited studies in determining the cost-effectiveness of PGS have 
been performed.  Murugappan, Ohno, & Lathi (2015) examined the current literature to 
determine if a cycle of IVF with PGS would be more cost-effective than expectant 
management.  The authors concluded that although IVF with PGS resulted in a lower 
clinical miscarriage rate than expectant management, it was a costlier technique with 
fewer clinical pregnancies. 
Other researchers have pointed to cumulative IVF pregnancy rates as a means to 
increase live birth rate.  In a study on cumulative birth rates, Luke et al. (2012) described 
the pregnancy rate for women who proceed to three cycles of IVF.  The authors found 
that if a women proceeds to at least three cycles of IVF, the live-birth rate can be similar 
to natural fecundity rates for women.  Other researchers have confirmed these findings 
and suggested that if women can proceed to three or more cycles, then a high (> 70%) 
live birth rate can be achieved  (Smith, Tilling, Nelson, & Lawlor, 2015).   
Cost-effectiveness analysis (CEA) for genetic tests and their use in healthcare 
have been described (Garber & Phelps, 1997; Grosse, Wordsworth, & Payne, 2008).  
Many authors have described genetic testing in the context of cost-utility and have 
determined that continued studies to understand the efficacy of genetic tests as they relate 
to economics must be performed, despite growing evidence that genetic tests provide 
improved outcomes and better health  (Phillips, Sakowski, Trosman, Douglas, Liang, & 
Neumann, 2014).   
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Considering CEAs specifically of PGS and IVF, the results have been mixed 
concerning the use of PGS.  Multiple researchers found no benefit to the use of PGS 
when compared with some other intervention. In a study examining the cost-effectiveness 
of two interventions, IVF combined with PGS and expectant management for patients 
with recurrent pregnancy loss, researchers found that expectant management was a far 
more cost-effective strategy that IVF in conjunction with PGS for patients with RPL, 
regardless of age group (Murugappan et al., 2015).  Further, Salem, Ho, Bendikson, 
Chung, & Paulson (2016) concluded that PGS in a fresh transfer was not cost-effective 
compared with IVF alone in patients older than 39.  The analysis was made using 
previous data concerning false positive rates in PGS (Salem et al., 2016).  Other 
researchers looked at similar retrospective data and determined that PGS with IVF was 
not a cost-effective strategy compared with IVF alone (Kushnir, Darmon, Albertini, 
Barad, & Gleicher, 2016).  However, in recent studies, researchers have looked at 
retrospective data to determine the cost per live birth with IVF and PGS compared to IVF 
with fresh transfers and subsequent frozen transfers in different cohorts of women.  
Hodes-Wertz, McCulloh, and Grifo (2015) conducted a recent single-center study by 
using direct costs for IVF and PGS and found that PGS was cost-effective in all age 
groups but women over 42.  Adding to that is the conclusion of Resetkova, Tobler, 
Kearns, & Werner (2013) who found all age groups saw cost-effectiveness benefits from 
the use of PGS.  
These contrary findings from recent CEA present a gap in the understanding of 
this technology in routine clinical practice.  Further, no studies have been performed 
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comparing IVF in conjunction with PGS in one cycle compared to three consecutive 
cycles.  Comparing the results of past studies for live birth rates in cumulative IVF cycles 
with live-birth studies from IVF combined with PGS will result in two end data points of 
the arms of a decision model and contribute to the current knowledge base of this nascent 
technology.    
Problem Statement 
There have been few health economic analyses for the use of PGS, and previous 
analyses were rooted in the technology and costs of the time, both of which have changed 
dramatically over the past few years (Gleicher et al., 2014).  To date, no CEA from the 
perspective of the payer (in most IVF cases, the patient) have been done to determine if 
PGS should be used during the first cycle of IVF, versus going on to have three 
consecutive cycles of IVF without PGS.   
The problem that I sought to solve with this research was to provide insight into 
the cost effectiveness of PGS testing in first cycle of IVF versus continued IVF cycles 
using a cost-effectiveness model for decision analytics.  I examined the potential 
outcomes using previously published data about live birth rates, PGS live birth rates, and 
costs based on public information and private clinic data.   
Purpose of the Study 
The purpose of the study was to understand the cost-effectiveness of genetic 
screening in IVF and determine its utility compared to multiple cycles of IVF using 
secondary sources of data.  For patients, IVF is expensive and is covered by health 
insurance in only a few states (Society for Assisted Reproductive Technologies, 2014).  
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For those reasons, it is important to know what interventions provide the best clinical 
outcomes at the lowest costs.  If the intervention of a genetic test adds cost in the short-
run, but saves costs in the long-run because of the clinical information it provides, then 
that intervention needs to be considered as a first-line therapy (Grosse et al., 2008).  
Because the health benefit is achieving a live birth, it is a more set endpoint than using a 
quality-adjusted life year (QALY), which is subjective.   
The importance of providing the best care while using the least resources is a 
critical part of reducing health-care expenditures in the United States while increasing 
quality of care.  Through CEA of the two interventions, I aim to shed light on which 
technique might be preferred in the clinic to help couples achieve a live birth (Garber & 
Phelps, 1997). 
Research Question and Hypotheses 
Research Question 
RQ1-Quantitative: What is the cost-effectiveness of IVF paired with PGS in one 
cycle compared to three consecutive cycles of IVF in achieving a live birth? 
RQ2-Quantitative: What are the statistical differences in means between cost-
effectiveness among women aged under 40, women aged 40-42, and women aged over 
40 of women in each treatment arm?   
Hypotheses 
Null Hypothesis (H0): There was no statistically significant difference in the cost-
effectiveness of proceeding to three cycles of IVF without PGS in achieving a live birth 
than one cycle of IVF with PGS. 
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Alternative Hypothesis (Ha): There was a statistically significant difference in 
cost-effectiveness in utilizing one cycle of IVF with PGS in achieving a live birth than 
three cycles of IVF. 
Variables 
The independent variable in this research problem was the method of treatment 
(Mt), either one cycle of IVF with PGS (IVF-PGS) or three cycles of IVF (3xIVF). 
The dependent variable was cost, or cost-effectiveness as determined via cost-
effectiveness ratio of costs/live birth.   
Theoretical Framework 
 The theoretical framework for this study was Rogers (1975) protection motivation 
theory (PMT) as it applies to genetic screening.  PMT describes factors that motivate 
people to do certain things when it concerns their health.  It focuses on cognitive 
processes and has three main components, including how the perception of severity of a 
health threat, the person’s vulnerability to that threat, and the efficacy of the proposed 
protective mechanism.  In this study, the health threat is pregnancy loss combined with 
economic threat of overpaying for an alternate intervention. Other researchers have 
described he literature describes the vulnerability, and the efficacy of the treatment arm is 
the clinical outcome.  PMT was used as a model for genetic screening, including BRCA 
testing (Helmes, 2002).   
Nature of the Study 
The research design was a cross-sectional study based on economic modelling, 
using secondary data from the current literature and public data sets to determine 
9 
 
incremental cost effectiveness ratios (ICER).  I utilized CEA and determined the results 
based on decision analytic models of two interventions to achieve a similar outcome.  
CEA is an economic tool used to compare costs and health outcomes of two 
interventions.  Utilizing decision analytic models, I compared two interventions to aid in 
decisions about treatment course.  Statistical analysis included sensitivity analyses to 
determine what key parameters provided the best outcome utilizing the least resources 
(Noyes & Holloway, 2004).  Utilizing a cost-effectiveness decision model, the costs 
associated with each intervention—either IVF-PGS or three cycles of IVF (3xIVF)—
were compared. 
Many CEA models utilize health benefit endpoints that may be arbitrary, like 
QALY.  Such endpoints are subject to interpretation about the costs associated with those 
benefits (Weinstein, Siegel, Gold, Kamlet, & Russell, 1997).  Because the costs 
associated with getting to a live birth are known with some certainty, CEA should 
provide the best method for understanding the decisions needed for that treatment.  
Definitions 
 Multiple clinical terms and their acronyms were used throughout the study and are 
defined in detail in Chapters 2 and 3.  A comprehensive list of all acronyms used in this 
study can be found in Appendix A.  Definitions of the most common terms are here: 
Assisted reproductive technology (ART): Any technology used to assist 
pregnancy.  It typically involves the manual handling of sperm or eggs, or both.   
Clinical miscarriage: Any pregnancy loss less than 20 weeks gestation. 
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Cost-effectiveness analysis (CEA): A type of economic analysis that assumes that 
one wants to optimize some outcome given some resource restraint.  Typically, this 
analysis results in a cost-effectiveness ratio, where the numerator is the net expenditure of 
health resources (costs) and denominator is the net improvement in health, or other 
health-related outcome, in this case, one live birth (Weinstein et al., 1997). 
Cycle or IVF cycle: Any number of embryo transfers from a single given oocyte 
retrieval event. 
In vitro fertilization (IVF): A form of ART where oocytes are retrieved surgically 
and then fertilized in vitro.  The fertilized embryo(s) are then implanted in to the women 
to facilitate pregnancy.   
Live birth: A live birth is defined as any pregnancy that terminates in a live birth 
after 24 weeks of gestation, where the child survived at least 30 days out of utero. 
Preimplantation genetic diagnosis (PGD): A type of genetic testing used to look 
for a specific disease in a fertilized embryo, such as Tay Sachs or Huntington’s Disease. 
Preimplantation genetic screening (PGS): A type of genetic screening used to 
determine if a fertilized embryo has the correct complement of chromosomes.   
Assumptions 
 As the analysis is done on a theoretical model, many of the assumptions were 
made based on the design of the model itself.  I assumed certain specific states for each 
intervention and the outcomes of those interventions, including technical assumptions 
that defined each cycle and the number of embryos transferred.  Further, the model 
assumed only three outcomes for any cycle: live birth, clinical miscarriage, or no 
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pregnancy.  I also assumed that no couples dropped out of IVF treatment between cycles, 
and I used clinical probabilities from the literature to account for that assumption.  No 
other outcomes were considered.  These methodological assumptions are detailed in 
Chapter 3.   
Scope and Delimitations 
 The scope of the study was limited to those patients who participated in the 
studies of the original datasets, and I looked only at the age of the participants as a factor 
in any differences between interventions.  Although the number of patients in each 
intervention arm is significant, each clinical case is different, so each outcome is not 
exactly the same.  This study’s scope included three consecutive cycles of IVF or one 
cycle of IVF with PGS.  These are not the only options available to patients wishing to 
conceive through ART.   
There were multiple threats to validity.  They included protocol-driven resource 
use, comparators that are uncommon or not recommended in clinical practice, 
nonrepresentative recruiting, restrictive inclusion and exclusion criteria, and artificially 
enhanced compliance (Ramsey et al., 2015).  These threats were mitigated by using 
secondary data that were not protocol specific and ensuring that each intervention arm 
was one used in clinical practice.   
Concerning specific delimitations of intrinsic limitations of the data or primary 
studies, I made every effort to normalize much of the data by using multiple sources and 
not relying on only one source for all data in the model.  Further, statistical tests were 
used to determine the confidence intervals of each cost-effectiveness ratio (CER), as well 
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as the sensitivity of any one or multiple variables in the model.  These statistical tests are 
recommended as best practice for modelling of CEAs (Briggs et al., 2012).   
Limitations 
 As in any CEA, the main limitation of the model was the input of the model itself 
(Ramsey et al., 2005).  Because clinical probability data for each intervention was drawn 
from both the literature and from public databases, there were intrinsic limitations about 
the design of the studies and the accuracy of the data reported by the CDC.  Further, any 
limitations of the original studies used to populate the data in this model also existed in 
this study. 
Significance of the Study 
 The significance of the study was in providing empirical data to support how a 
patient might go about getting pregnant through the use of IVF.  As healthcare costs 
continue to rise, it is important to know if genetic screening tests can determine cost-
effectiveness for certain patients in order to achieve certain health outcomes (Grosse et 
al., 2008).  Understanding the different costs associated with multiple interventions to 
achieve a live birth is significant for society and also helps clinicians and the healthcare 
industry understand how new technologies benefit society.  No studies on this have been 
done to date, so the research was novel.    
Summary 
 IVF is a relatively expensive procedure and most patients in the United States 
must pay it out-of-pocket.  Genetic screening for embryos has been shown to be an 
effective way to increase live birth rates and improve the effectiveness of IVF (Keltz et 
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al., 2013; Yang et al., 2015).  Further, studies have shown that undergoing multiple, 
consecutive cycles of IVF also results in a high live birth rate (Smith et al., 2015).  There 
have been multiple CEAs comparing the use of PGS in clinical practice compared to 
other interventions.  The conclusions from those studies have been mixed, with some 
authors stating that PGS is not cost-effective, some saying it is cost-effective for only 
some age groups, and others stating that it is cost-effective for all age groups (Hodes-
Wertz et al., 2015; Mersereau, Plunkett, & Cedars, 2008; Resetkova et al., 2013).  
Because there is no clear consensus between industry experts and clinicians, this presents 
a significant gap in the understanding of genetic screening in the use of routine clinical 
practice.  To date, no cost-effectiveness studies have been performed that compare the 
cost-effectiveness of having IVF combined with PGS in one cycle, compared to three 
consecutive cycles of IVF.   
 The methodology I used is a decision-analytic model comparing two interventions 
using secondary sources of data.  The two interventions were IVF paired with PGS in one 
cycle and IVF without PGS for three consecutive cycles.  The study was a CEA, and I 
examined the cost-effectiveness ratios of each intervention as costs per live birth.  The 
ratios were compared to provide an incremental cost-effectiveness ratio and statistical 
methods including sensitivity analyses were used to determine the robustness of the 
model.  The model assumes certain clinical states for each intervention and was limited 
by the intrinsic limitations of the original data.   
 Chapter 2 provides details of the current base of knowledge in the field of IVF 
and genetic screening.  It will also include discussion of the theoretical foundation of the 
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protection motivation theory.  Lastly, I will detail the current literature in cost-
effectiveness for genetic screening in general and in conjunction with PGS and IVF 
procedures and techniques.   
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Chapter 2: Literature Review 
Introduction 
 IVF is a type of ART used to facilitate pregnancy in a woman and eventually lead 
to the clinical outcome of a healthy, live birth (Van Voorhis, 2007).  The clinical 
effectiveness of IVF as a technique to achieve pregnancies and live births is well 
documented, and clinics that perform IVF are federally required to report their outcomes 
to the Centers for Disease Control (CDC) and voluntarily to the Society for Assisted 
Reproductive Technology (SART; Sunderam et al., 2015).  In 2014, the most recent year 
for which data are available, there were 208,604 cycles of IVF performed in the United 
States, with a combined national average of 30% of cycles leading to a live birth for 
women aged 35-37, 19.5% for women aged 38-40, and 9.7% for women aged 41-42 
(CDC, 2016). 
Other data has suggested that cumulative IVF pregnancy rates increase as a 
woman goes through more than one cycle of IVF.  In a study on cumulative birth rates, 
Luke et al. (2012) found that if a women proceeds to at least three cycles of IVF, the live-
birth rate can be similar to natural fecundity numbers for women.  Other studies have 
confirmed these findings and suggested that if women can proceed to three or more 
cycles, then a high (> 70%) live birth rate can be achieved  (Smith et al., 2015).   
 PGS, also known as comprehensive chromosomal screening (CCS), is a genetic 
technique used to analyze the complement of chromosomes from an individual embryo 
and determine if it is normal (euploid) or abnormal (aneuploid).  This type of screening is 
now typically done using (aCGH) or NGS and has been shown to greatly increase 
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pregnancy rates and live birth rates, depending on the age of the population studied 
(Hodes-Wertz et al., 2012; Yang et al., 2012).  Recent studies have continued to highlight 
higher live birth rates by using some form of PGS versus just IVF without genetic 
screening (Feichtinger et al., 2015).  The use of PGS in clinical care is controversial, and 
no clear recent consensus is available for patients or clinicians on when and where to use 
PGS in conjunction with IVF (Brezina & Kutteh, 2015).    
CEAs are economic models based on data that provide economic endpoints per 
some health benefit, also known as a cost utility ratio, or ICER.  These ratios usually 
have a quality adjusted life year (QALY) as the denominator, but many CEAs in fertility 
studies use pregnancy rate or live birth as the health benefit  (Grosse, Wordsworth, & 
Payne, 2008).  A more concrete outcome measure may be easier to effectively quantify, 
like live births.   
CEA in IVF is usually performed from the perspective of the payer, which is 
almost always the patient.  A few cost-effectiveness studies have been performed to 
examine different methods for IVF, live births, and outcomes, as well as to utilize 
decision models to understand the differences in interventions (Crawford et al., 2016; 
Fiddelers et al., 2009).   
The purpose of this quantitative study is to assess the cost-effectiveness of two 
different interventions involved with advanced reproductive technology in achieving a 
live birth.  I will also examine the variation of cost-effectiveness for each intervention by 
age group.  Only a few researchers have looked at cost-effectiveness associated with PGS 
and IVF, and none have examined cumulative IVF compared with one cycle of IVF with 
17 
 
PGS.  In a study on the cost effectiveness of IVF alone compared to IVF paired with PGS 
in women aged 38-40 and in women over 40, Mersereau et al. (2008) found that for 
women aged 38-40, IVF without PGS was more cost effective than with PGS, but for 
women over 40, the cost effectiveness was similar.  The study did not take into account 
the effects of multiple cycles on cost and percentage of having a live birth, nor did it take 
into account the most recent technological advances associated with PGS, like NGS.   
More recently, Murugappan et al. (2015) examined the cost-effectiveness for 
women with recurrent pregnancy loss with either expectant management or with IVF 
paired with PGS.  The authors concluded that expectant management was far more cost-
effective than IVF with PGS.  However, Murugappan et al. did not look at multiple 
cycles of IVF compared to one cycle with PGS.  The lack of research in the literature 
comparing these two typical interventions provides a unique opportunity to understand 
the cost effectiveness of PGS testing in first cycle of IVF versus continued IVF cycles 
using a cost-effectiveness model for decision analytics.   
Lastly, a recent abstract presented at the American Society of Reproductive 
Medicine looked at false positive rates for PGS and determined that because of false 
positives, women over 39 would have a decreased cost effectiveness to use IVF in 
conjunction with PGS (Salem et al., 2016).  The additional factor of false positives to the 
CEA has not been examined before.   
In this literature review, I will describe the literature search strategy I used 
followed by a review of the theoretical foundation of the study.  I will also provide 
technical background on infertility, assisted reproductive techniques, in vitro fertilization, 
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and PGS.  Lastly, I will review the current literature about cost-effectiveness of PGS as it 
relates to IVF and live birth rates.   
Literature Search Strategy 
For the literature search, I targeted multiple keywords followed by a snowball 
search approach to subsequent literature.  Because some of these technologies are new 
and rapidly evolving, I limited the technical and clinical searches for PGS and IVF to the 
past ten years, and often only reviewed articles published in 2012 or later.  Search terms 
were used individually and together in Boolean search terms of AND or OR.  Key search 
terms were the following : 
• Assisted reproductive technology (ART) 
• Centers for Disease Control (CDC) 
• Comprehensive chromosomal screening (CCS) 
• Cost-effectiveness analysis (CEA) 
• Cumulative IVF 
• Economic analysis 
• Genetic screening 
• In vitro fertilization (IVF) 
• Live birth rates 
• Preimplantation genetic screening (PGS) 
• Protection motivation theory (PMT) 
• Regulation of IVF 
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Theoretical Foundation 
The theoretical framework for this study was Rogers’s (1975) protection 
motivation theory (PMT) as it applies to genetic screening.  PMT is used to describe 
factors that motivate people to do certain things when it concerns their health.  It focuses 
on cognitive processes and has three main components, including how the perception of 
severity of a health threat, the person’s vulnerability to that threat, and the efficacy of the 
proposed protective mechanism.  In this study, , the health threat is pregnancy loss 
combined with economic threat of overpaying for an alternate intervention.  The 
literature describes the vulnerability, and the efficacy of the treatment arm is the clinical 
outcome.  PMT is used as a model for genetic screening, including BRCA testing 
(Helmes, 2002).  Rogers (1975) introduced PMT to describe how people deal with a 
perceived threat and how the level of fear of a certain outcome will change behavior and 
can be used to predict how much a threat has to be feared in order for someone to change 
his or her behavior (Boer & Seydel, 2005).  Further, PMT can be used to explain the 
decisions and communication factors that apply when people decide to undergo a 
potentially prophylactic procedure, intervention, or test. 
 Genetic screening is just such an intervention and PMT is applied to understand 
the level of apprehension about a potential adverse outcome in compelling someone to 
take on the risk of screening.  Further, Rogers (1975) describes two constructs that lead to 
a certain protective behavior.  The first is the threat appraisal, which is the aggregation 
of all the factors that increase the likelihood of a protective response, like the perceived 
vulnerability to and severity of the health threat (in this case, an adverse IVF outcome 
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like an inability to implant or miscarriage), minus those factors that decrease the 
probability of a protective response, like costs or risks of the procedures.  The second is 
the coping appraisal, formed by taking one’s appraisals of self-efficacy (can I do it?) and 
response efficacy (will it work?) minus the financial aspect with the behavior (Ralph et 
al., 2014).  
 For genetic testing, PMT has been applied to describe the factors that contribute 
to the decision to undergo genetic protective testing.  Helmes (2002) described the 
components of PMT that affected a woman’s choice to have BRCA testing for breast 
cancer risk.  While the author did not find every component of the PMT applied, the main 
factors such as fear, response efficacy, and costs played into the decision-making.   
 Only one study included the determinants of election to undergo PGS in the 
clinical setting.  Gebhart, Hines, Penman, & Holland (2016) found that several factors 
that correspond to the PMT contribute to the patient-perceived determinants when 
choosing to accept or decline PGS, including “cost, religious and ethical beliefs and 
values, social and family support, provider influences, and the past reproductive 
experience of the patient” (Gebhart, Hines, Penman, & Holland, 2016). 
 For this study, I utilize PMT as the framework for the decision-making process 
involved with genetic screening.  As this is an economic evaluation, I examined only the 
cost factor of PGS as a component of the PMT, although response efficacy (clinical 
outcomes) plays into the costs associated with PGS.   
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Literature Related to Key Variables and Concepts 
Infertility 
 Infertility is clinically defined as the inability to conceive after one year of 
unprotected sexual intercourse, and affects approximately 10% of the population (Van 
Voorhis, 2007).  Common reasons for female infertility include polycystic ovarian 
syndrome, a condition where a woman has a hormone imbalance issue, or primary 
ovarian insufficiency, a condition that is equivalent to early-onset menopause.  Male 
infertility occurs less often, but can also contribute to a couple’s infertility.  Overall, a 
woman’s age is the primary predictor of ability to conceive and have a healthy live birth 
(U.S. Department of Health and Human Services, Office on Women’s Health, 2009).   
 Infertility may be treated through consultation with a medical professional that 
specializes in infertility.  These specialists are reproductive endocrinologists and 
infertility physicians, (REI), and are board-certified obstetricians and gynecologists that 
have advanced training in the form of two or three year surgical fellowships 
(Accreditation Council for Graduate Medical Education, 2016).  The American Society 
for Reproductive Medicine has defined other conditions separately from infertility but 
related to it, such a recurrent pregnancy loss (RPL).  RPL is defined as a disease defined 
by two or more failed pregnancies of unknown etiology (“Definitions of infertility and 
recurrent pregnancy loss,” 2013).  Both infertility and recurrent pregnancy loss may be 
treated with the use of assisted reproductive technologies.   
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Assisted Reproductive Technology 
 The CDC (2014) defined assisted reproductive technology (ART) as any 
technology that involves handling both the sperm and eggs of human for the purposes of 
assisting reproduction.  ART was  introduced in the United States in 1981 by the birth of 
the first infant using techniques where eggs are surgically harvested, fertilized, and 
implanted in a woman (Sunderam et al., 2015).  ART can include techniques such as IVF, 
gamete intrafallopian transfer (GIFT), pronuclear stage tubal transfer (PROST), tubal 
embryo transfer (TET), and zygote intrafallopian transfer (ZIFT)  (American Society of 
Reproductive Medicine, 2015).  
 Other treatments for infertility exist, including intrauterine insemination (IUI), 
which involves injecting sperm into the uterus at the exact time of ovulation.  REI may 
also choose to perform other surgical techniques to repair anatomical issues affecting 
infertility, or other drug therapies to aid in either male of female infertility problems.  
While many options exist for the treatment of infertility and RPL,  IVF will be the focus 
of this study. 
In Vitro Fertilization 
 IVF, combined with embryo transfer (ET), is a type of ART where a physician, 
typically a reproductive endocrinologist, uses hormonal stimulation drugs to induce a 
woman to ovulate multiple eggs.  The eggs are then surgically harvested from the woman 
and put into a petri dish alongside sperm collected from a male partner.  The sperm 
fertilizes the eggs in vitro, either naturally, or through an intervention known as 
intracytoplasmic sperm injection (ICSI).  ICSI is a technique where an embryologist 
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collects sperm in a fine needle and injects one sperm into an egg, or oocyte, to commence 
fertilization.  Once fertilization occurs, the resultant embryo is cultured for several days 
and then implanted into the uterus of the woman (Van Voorhis, 2007). 
 IVF has gone through a series of developments in technology over the years since 
Georgeanna and Howard Jones opened the first IVF clinic in the United States in 1980.  
However, the main tenets of IVF remain the same as when introduced.  The process starts 
when a physician uses human menopausal gonadotropins (hMG) to stimulate the 
woman’s ovary to ovulate multiple oocytes for retrieval and then retrieve them surgically.  
These gonadotropins can include follicle-stimulating hormone (FSH) and human 
chorionic gonadotropin (hCG), as well as other formulations of gonadotropins under 
various trade names (Jungheim, Meyer, & Broughton, 2015).    
 The oocytes are retrieved surgically by the reproductive endocrinologist, and the 
goal will be to remove as many oocytes as possible during the ovulation cycle.  The 
reason for retrieving as many as possible is to attempt to create as many embryos as 
possible to have multiple options for implanting a healthy embryo back into the mother.  
This practice has led to an increase in multiple births over the years and has also led to a 
wave of concern about implantation of multiple embryos (Kulkarni et al., 2013).  
 Once the oocytes are retrieved, an embryologist, a scientist trained in the handling 
and evaluation of embryos as well as ART, will commence the fertilization process 
starting with fertilization of the oocyte on Day Zero (0) (Niakan, Han, Pedersen, Simon, 
& Pera, 2012).  This process happens either through IVF, sometimes called natural 
fertilization, or through ICSI.  Clinicians will utilize either approach depending on the 
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clinical presentation and screening prior to ART.  Some studies suggest that in non-male 
factor infertility, ICSI does not provide any benefit over natural IVF (Eftekhar, 
Mohammadian, Yousefnejad, Molaei, & Aflatoonian, 2012).   
 Regardless of how fertilization occurs, an embryo will form and go through 
different stages of development.  See Figure 1 for an illustration of this process.  In 
general, egg and sperm will form a zygote and then start to divide in stages of one-cell, to 
two-cells, to four-cells, and then 8-cells by day 3.  At this point, the embryo has 
developed into a morula, and then will turn into a blastocyst.  This process generally 
takes 5-6 days from day 0 when fertilization occurs (Niakan et al., 2012).   
 As the embryo develops, the embryologist will grade the embryos daily through 
the use of morphology.  Morphology is the process of examining the embryos under a 
microscope.  There are different methods and criteria for grading and evaluating 
embryos, and no firm standard exists in the community for morphology grading, despite 
global efforts to standardize these non-invasive assessments (Alpha Scientists in 
Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011). 
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Figure 1. Stages of human pre-implantation embryo development. Reprinted from 
Niakan et al., 2012.  
 
 The physician and the mother may elect to perform fresh embryo transfer (ET) 
when the embryo is in the Day 3, or cleavage, phase, or a frozen embryo transfer (FET) 
when the embryo is in the blastocyst stage at Day 5/6.  Studies have shown that 
blastocyst transfers can result in higher implantation rates, but do not significantly alter 
the live birth outcomes if a birth is achieved (Maxwell, Melzer-Ross, McCulloh, & Grifo, 
2015). 
 The American Society for Reproductive Medicine (2013) has provided guidance 
on blastocyst transfer at the discretion of the physician and only in good prognosis 
women.  Systemic reviews have determined that FET, when used in good prognosis 
patients, increases the chances of achieving a live birth and decreases miscarriage rates 
(Roque et al., 2013).  However, there is evidence that fresh blastocyst-stage transfers do 
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not significantly impact live birth rates compared to fresh cleavage stage transfers 
(Glujovsky & Farquhar, 2016).   
 Whether a woman elects to do a frozen or fresh embryo transfer, she must also 
decide to implant one embryo, known elective single embryo transfer (eSET), or multiple 
embryos.  Multiple births is a side-effect of ART over the last thirty years and multiple 
births (twins, triplets, etc.) have increased dramatically specifically because of ART 
(Kulkarni et al., 2013).  One way to decrease the rate of multiple births is to only implant 
one healthy embryo.  eSET, combined with CCS or PGS, has shown promise in 
decreasing costs and reducing live birth rates (Crawford et al., 2016).   
 While the American Society for Reproductive Medicine maintains certain 
opinions about best practices for IVF and embryo transfer, there are no standard ways of 
doing things form ART clinic to ART clinic, and multiple factors go into how an REI 
treats infertility (Van Voorhis, Thomas, Surrey, & Sparks, 2010).   
Preimplantation Genetic Screening 
 PGS, also known as comprehensive chromosomal screening, is a genetic test that 
uses a number of different technologies in order to determine the ploidy (number of 
chromosomes) of an embryo while it is still in vitro.  The goal of PGS is to determine 
which embryos are euploid (normal number of pairs of chromosomes, 23) or aneuploidy 
(abnormal number of pairs).  Aneuploidy is a major factor in women having 
miscarriages, either with the use of ART or not (Liu et al., 2012).  Euploid embryos are 
selected for implantation in the uterus as part of IVF.  This should be differentiated from 
other preimplantation genetic tests, such as preimplantation genetic diagnosis (PGD), 
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which looks at a specific disease that is known to be carried by one or both parents 
(Brezina & Kutteh, 2015). 
 An embryologist performs PGS by removing one or multiple cells from a growing 
embryo after fertilization in vitro.  This occurs either at the cleavage stage (Day 3, or 8-
cell stage) for a removal of one cell for analysis, or at the blastocyst stage, where tens or 
hundreds of cells are removed from the trophectoderm at Day 5 or 6.  Generally, when a 
Day 5 or 6 embryo biopsy is performed, it is always in conjunction with vitrification 
(freezing) of the embryos for FET (Brezina & Kutteh, 2015).  While both types of 
embryo transfers are done in the United States, there is a growing body of clinical 
evidence that frozen transfers are the preferred technique in order to get the most optimal 
clinical outcomes (Maxwell et al., 2015). 
Multiple technologies exist that can be used to establish the ploidy of an embryo.  
They include fluorescent in-situ hybridization (FISH), quantitative polymerase chain 
reaction (qPCR, or quant PCR), aCGH, and NGS, also known as high-throughput 
genomic sequencing.  Many in the field refer to PGS performed by FISH or qPCR as 
“PGS#1”, and NGS and aCGH technology as “PGS#2”.  This is to indicate the extreme 
clinical differences between the two sets of technologies (Gleicher et al., 2014).  
Generally, PGS performed before 2011 in the United States is considered PGS#1, and 
PGS performed after 2011 is considered PGS#2 (Yang et al., 2012). 
 Each platform has its advantages and disadvantages, but aCGH has the most 
relevant data associated with higher implantation rates and live births than any of the  
other technologies (Capalbo et al., 2015; Handyside, 2013).  NGS is a relatively new 
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technique to perform ploidy analysis, but has shown itself to be just as effective at 
screening for euploid embryos as aCGH (Yang et al., 2015).  Table 1 describes the 
different technologies as they relate to PGS.  This study will focus on live birth rates 
from PGS#2 technologies, and will imply PGS#2 when the term “PGS” is used.  It will 
also assume that there is no difference in NGS v. aCGH.   
Table 1 
Different Technologies for PGS  
Method Turn-around 
time 
 
Costs to run Resolution PGS #1 or #2 
FISH 24 hours Low Low 1 
qPCR 4 hours Low Low 1 
aCGH 12-24 hours Medium Medium 2 
NGS 16-72 hours Medium-low Low 2 
Note. Adapted from Handyside, 2013, p. 598.  
 
 Concerning the clinical efficacy of PGS, multiple investigators have reported their 
findings and have concluded that the use of PGS in conjunction with IVF/ICSI can yield 
higher implantation rates, on-going pregnancy rates, and live birth rates, regardless of the 
age of the woman (Dahdouh, Balayla, & García-Velasco, 2015; Keltz et al., 2013; 
Munné, 2012; Yang et al., 2012).  Other studies have looked specifically at certain age 
groups to determine clinical efficacy.  One such study examined the outcomes of live 
birth for women aged 40-43.  The study was a retrospective cohort study that examined 
450 cycles that did not have PGS, and 170 where PGS was employed along with FET.  
The authors found significantly higher live birth rates for FET with PGS than without 
PGS, 45.9% compared to 19%, respectively (Lee et al, 2015). 
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 In a recent retrospective study, researchers examined the data from the CDC for 
the years 2011 and 2012 to determine live birth rates by age when PGS was used.  The 
authors found that there were 5,467 PGS cycles compared to 97,069 non-PGD/PGS 
cycles during that timeframe.  The authors concluded that of the PGS cohort, PGS did not 
increase live birth rates for women less than 35 years old, but did improve live birth rates 
among women over 37 years old (Chang, Boulet, Jeng, Flowers, & Kissin, 2016).   
 Multiple systemic reviews of the literature on PGS were conducted in the past six 
years.  The first, conducted in 2011, showed no benefit to PGS with IVF for any age 
group based on the literature to date (Mastenbroek, Twisk, van der Veen, & Repping, 
2011).  In fact, that review concluded that the use of PGS lowered live birth rates in 
women aged over 40 compared to IVF alone, and that no significant benefit was seen in 
any age group.  However, the literature at the time was limited to studies using PGS#1 
only, and did not take into account any studies using aCGH or NGS.   
Dahdouh et al. (2015) found PGS did improve embryo selection and implantation 
rates based on three RCTs and eight observational studies reviewed.  While the authors 
did see live birth rates in a few of the studies, they did not report on the statistical 
significance of those outcomes.  They also did not resolve PGS by age group.  Further, 
the authors discuss the needs for further examination of PGS with IVF, especially in 
conjunction with cumulative IVF.   
 Lee et al. (2015) conducted a systematic review that included three RCTs and 16 
observational studies.  The authors concluded that the majority of the studies and RCTs 
showed that PGS provided improved implantation rates and ongoing pregnancy rates.  
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They also concluded that not enough evidence was provided to make meaningful 
conclusions concerning age group stratification.   
 Other researchers attempted to examine the efficacy of PGS via systematic review 
for women of advanced maternal age (AMA).  The authors searched the databases in 
2010 and found six RCTs that met their inclusion criteria.  The authors found that PGS in 
women with AMA showed significantly lower live birth rates than without PGS.  
However, the authors noted that the methodologies, techniques, and technologies used for 
all of the reviewed papers varied widely (Noble et al., 2010).  Like some of the other 
earlier papers on this issue, PGS #1 technologies such as FISH were predominantly seen 
in these studies.   
 Lastly, Chen, Wei, Hu, and Quan (2015) conducted a meta-analysis of PGS 
studies to date. For live birth rates, the four studies examined that discuss this outcome 
show an average live birth rate using PGS of 65.6%.  The studies examined all had 
different patient populations and looked at differing embryo transfer methods, such as 
SET or DET.  Forman et al. (2012) looked at only SET, possible resulting in the lower 
live birth rates than the other studies.  Concerning age, the one RCT did not discriminate 
based on age, and the three other studies examined women of different age groups, either 
older than 35 or younger.  There was no conclusion drawn by the authors as to efficacy 
by age group.  Table 2 is adapted from that study and compares the most relevant studies 
where live birth rates are the outcome.   
31 
 
Table 2 
Studies examining live birth rate for PGS and non-PGS 
Study Type 
of 
Study 
PGS live 
births / total 
 
PGS Live 
Birth Rate 
Non-PGS 
(Control 
group) live 
births / total 
Non-PGS 
Live Birth 
Rate 
Scott et al., 2013 RCT 61/72 84.7% 56/83 67.5% 
Forman et al., 
2012 
Cohort 49/140 35% 63/182 34.6% 
Greco et al., 
2014 
Cohort 59/88 67% 7/33 21% 
Schoolcraft et 
al., 2010 
Cohort 34/45 75.6% 78/113 69% 
Note. Adapted from Chen et al., 2015, p. 10/21. 
 
 Despite the evidence, PGS remains controversial and is not recommended by any 
of the medical groups that govern the space, such as the American College of 
Obstetricians and Gynecologists (ACOG)  or the American Society for Reproductive 
Medicine (ASRM) (“ACOG Committee Opinion No. 430,” 2009).  Many continue to 
doubt the clinical usefulness of PGS, and have suggested that non-PGS embryo selection 
would lead to higher live birth rates than performing PGS  (Gleicher et al., 2014; Orvieto, 
2016).    
Trends in PGS Adoption 
 Despite the lack of consensus on routine clinical use of PGS, it continues to see 
increasing adoption among individual practices in the United States.  The CDC has 
reported PGD rates for years but only for 2014 has the term “PGS” been added to clarify 
it is included with this rate.  The CDC does not break out PGS versus PGD, however, so 
the exact trends are difficult to ascertain (Sunderam et al., 2015).  Despite this, the overall 
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trend of all clinics reporting in the United States has ranged between 3 and 5% for the 
past five years (CDC, 2016).   
 Others have reported increased clinical usage overall in the United States from 
2014 to 2016, years that are not covered by CDC statistics.  A recent paper highlighted 
the increasing trend in PGS use in the U.S., mainly due to the advanced technologies of 
aCGH and NGS and better understanding of FETs.  Some have estimated a 30% increase 
in PGS utilization per year since 2014.  Some have also suggested a more accurate PGS 
utilization rate of 8% of all cycles (Mastenbroek & Repping, 2014). 
 Based on the available data, it is clear that each clinic views the use of PGS 
differently.  The CDC data for 2014 shows an overall rate of PGD/PGS of 4%, however, 
there are clinics that report 0% PGD/PGS rates and others that report 86% of all cycles 
utilize PGD/PGS (Centers for Disease Control and Prevention, 2016).  Some clinics 
advocate only frozen transfer and recommend PGS for every patient regardless of age 
(“IVF Success Rates with PGS | Arizona IVF Clinic,” n.d.).  The fact that every clinic has 
a different view of PGS makes this one of the most controversial aspects of this 
extremely important clinical decision.  Mastenbroek and Repping (2014) state:  
In our view evaluating the (cost-)effectiveness of medical treatments is by far the 
greatest challenge in current day medicine, especially in an era where health care 
costs continue to increase to the extent where they are the number one item of 
expense for many governments across the globe.   
This is why the CEA proposed in this study fills a gap in the literature and why it is adds 
to the growing body of evidence for the adoption of this technology. 
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Regulation of IVF 
 IVF has been a useful tool for several decades now and has proven to be a 
successful option for women and men with infertility.  Since the inception of ART, there 
have been concerns about the regulation of this nascent technology and how it affects 
consumers and patients.  In 1992, Congress enacted the Fertility Clinic Success Rate and 
Certification Act of 1992 (FCSRCA) (Public Law 102–493).  This act mandated that all 
clinics performing these advanced reproductive techniques report their success rates via 
various metrics to the government, specifically, the CDC, in a standardized manner 
(CDC, 2016).   
 The FCSRCA requires clinics performing ART to report certain metrics, and they 
include live birth rates and PGD/ PGS rates.  Data is collected via a web-based tool 
known as the National ART Surveillance System (NASS), and in 2013 over 94% of all 
U.S. clinics performing ART reported their results (Sunderam et al., 2015).  These results 
are meant to guide prospective patients to understand each reporting clinic’s success rate 
for performing ART, and assist with the selection of a potential IVF clinic.  Further, the 
CDC aggregates this data year-by-year for analysis of trends in the space (CDC, 2016). 
 Other regulatory considerations of IVF include payment and insurance coverage.  
Most states do not require health insurance companies to provide coverage for IVF and 
/or ICSI, and no states mandate coverage of PGS (National Conference of State 
Legislatures, 2014).  Of the few states that do mandate coverage, studies have found that 
birth rates increase due to the elimination of the financial aspect of doing multiple cycles 
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of IVF (Boulet et al., 2015).  Further analyses of this kind are needed to dictate future 
policy for insurance coverage of IVF.   
Cumulative IVF 
 Achieving implantation, on-going pregnancy, and ultimately, a live birth, using 
ART involves many factors.  One such factor is the number of attempts made by using 
IVF, or the cumulative success rate of multiple cycles of IVF.  While the data reported by 
the CDC provides details of success rates in cycles, it does not take into account any 
cumulative or multiple cycles, thus limiting our understanding of the actual success rates 
per cycle (Sunderam et al., 2015).  To date, there is limited data to clarify how linking 
IVF cycles contributes to live birth rate success rates.  However, two studies shed some 
light on the issue. 
 The first study was an analysis of CDC data to estimate live birth rates.  Of 
471,208 cycles from 2004 to 2009, there were 140,859 live birth rates.  Overall, the 
authors estimate that by the third linked cumulative cycle of IVF, the conservative live 
birth rate estimate for all women is 52.4%.  The authors conclude that the rate of natural 
fecundity can be achieved through linked IVF cycles.  They also find that maternal age is 
the major factor in all live birth rate trends (Luke et al., 2012). 
 The second study is more recent and is a prospective study that examined the live 
birth rate for 156,947 in the UK that underwent multiple cycles of IVF from 2004 to 
2010.  Results showed that the conservative estimate of cumulative live birth rates for 
women undergoing at least three cycles of IVF was 44.6%.  The authors were also able to 
stratify these results by age group and for women using their own oocytes, and the results 
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showed the conservative estimates by cycle #3 for ages <40, 41-42, and > than 42 to be 
48.6%, 18.5%, and 5.4%, respectively (Smith et al., 2015). 
 Both studies make assumptions about patients that drop out after each successive 
cycle of IVF.  Drop-out rates from IVF treatment have been reported between 17-65%, 
depending on the age of the woman, treatment schedule, and which number of cycles of 
treatment (Luke et al., 2012; Verberg et al., 2008).  Calculating the cumulative birth rates, 
therefore, require certain assumptions for those patients that dropped out.  In the Smith et 
al.’s (2015) study, their conservative estimates assumed that all of the patients that 
dropped out in a previous cycle would have achieved a live birth rate of 0% had they 
stayed in treatment.  Reasons for dropping out include mental stress, financial issues, and 
other psychological factors (Verberg et al., 2008).   
 To date, there have been no studies that compare the cost-effectiveness of the use 
of PGS in IVF/ICSI with multiple cycles of IVF without PGS.  The ability for a patient to 
assess their options in IVF treatment and to make decisions based on all the factors 
associated with likely outcomes is critical to societal change. CEAs aid in understanding 
the economic impact of making decisions and is a factor of decision-making as it relates 
to the protection motivation theory.  
Cost-effectiveness Analysis 
 CEA is a kind of economic analysis that attempts to quantify the overall costs of 
something and compare them to some outcome.  In a CEA for medical applications, the 
idea is to provide insight about the most cost-effective option between two or more 
interventions, considering health outcomes.  It can also be defined as an analysis where 
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one wishes to maximize some objective (health outcomes) given a limited resource 
(money).  It is a form of economic analysis and can be contrasted with cost-benefit 
analysis (CBA), where a CBA expresses all outcomes as a monetary unit, and a CEA will 
attempt to quantify the effectiveness compared to a relatively qualitative amount such as 
health outcomes (Grosse et al 2008).  This unique idea gave rise to the idea of the ICER 
and the quality-adjusted life year (QALY). 
 An incremental cost-effective ratio is the basis for all CEAs for medical 
applications.  It consists of a numerator that consists of the monetary amount of the net 
expenditure of health resources divided by a denominator of the incremental benefit of 
the health improvement, a non-monetary measure (Weinstein et al., 1997).  An area of 
debate in this field remains what should be included in both numerator and denominator 
to best capture the overall cost-effectiveness of some intervention over another.   
 The numerator should consist of all the factors that express the net economic 
benefit of some intervention.  This can include direct costs of the intervention, either 
fixed or variable, long-run opportunity costs, labor costs, or some variation of all of these.  
It can also include costs saved, or economic benefits gained.  Many economists have 
agreed on the need to define clearly what costs, savings, and/or benefits are being 
measured in a CEA in order to understand the net economic improvement (Weinstein, et 
al, 1997). 
 The elements of the denominator are an even more complicated issue.  Many 
attribute the introduction of the QALY to Weinstein and Stason (1977) in their 
groundbreaking work concerning hypertension.  A QALY attempts to quantify the 
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extension of life (or the minimization of pain) through quantification from zero to one, 
where zero represents death and one represents perfect health.  The QALY framework is 
designed to be applied in any disease-state because of the flexibility of the quantification 
of the health outcome via some instrument such as the EuroQol (Meltzer, 2001).  These 
instruments seek to capture the level of health outcome from zero to one, and can be 
highly subjective.   
 CEAs have been used in recent years for both genetic screening techniques in 
many fields as well as in IVF for a multitude of purposes.  These CEA provided insight 
into best practices to use for both genetics screening and IVF and can be applied to this 
study.   
CEA in Genetic Testing and Screening 
 Genetic testing, such as PGS, provides a unique set of challenges for economists.  
While such testing holds promise to provide better diagnoses, eliminate unnecessary 
procedures, and predict future disease risk, the impact of such testing is still very new and 
therefore the timeline and costs associated with this testing is difficult to capture.  An 
analysis of economic evaluations of genomic technologies showed that measuring 
outcomes is problematic and that the costs captured in the numerator of an ICER vary 
from study to study by costs captured, timeline, and scope (Buchanan, Wordsworth, & 
Schuh, 2013). 
 A number of studies examine genetic testing and their cost-effectiveness, and as 
described, vary in application, scope, and outcomes.  One study looked at the CEA of 
OncotypeDX (Genomic Health, Redwood City, CA), a commercially available genetic 
38 
 
test that discriminates patients based on genetic markers for chemotherapy intervention.  
The study utilized a Markov decision model with 146 patients who either decided to use 
the test or not, and incremental cost ratio was overall costs for either intervention divided 
by a QALY-based score that encompassed longevity, recurrence, and other factors.  The 
results were in a better cost-effectiveness ratio with the test than with standard care (Holt 
et al., 2013). 
 Another similar study sought to understand the CEA of a commercially available 
test for non-small cell lung cancer (NSCLC), known as VeriStrat (Biodesix, Boulder, 
Co.).  The study looked at two outcomes from the perspective of the U.S. payer, cost per 
QALY gained and total direct lifetime costs. Again, the authors used a Markov decision 
model to look at two interventions – with the test and without the test.  They made 
assumptions about the timeline of the costs captured through either intervention and used 
published data to compare clinical effectiveness of the test.  The authors found that use of 
the test was more cost-effective than standard treatment without the test (Hornberger, 
Hirsch, Li, & Page, 2015).   
 In both studies, similar analytical and statistical methods were used, including 
Markov decision analytics, one-way sensitivity analyses, and probabilistic sensitivity 
analyses (PSA).  Because genetic testing is rapidly evolving, CEAs of this kind of testing 
are a challenging field.  Some have recommended methods that go beyond traditional 
CEA for this kind of intervention, including using cost-benefit and cost-utility 
assessments to better understand the decisions for consumers to use such tests (Grosse et 
al, 2008).  Decision-making associated with genetic screening is part of the protection 
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motivation theory, where economic impact is one factor in making the decision to have 
the intervention.     
CEA in IVF  
 There are multiple articles describing the costs and cost effectiveness of IVF, IVF 
with ICSI, eSET, and PGS, although each one varies in the scope, timeframe, and costs 
included as previously discussed. Further, studies examining the outcomes and reporting 
for economic evaluations involving fertility find that the time horizon, costs included, and 
outcome endpoints differ from study to study and that the intervention being studied may 
be biased (Goldhaber-Fiebert & Brandeau, 2015).  These findings are consistent with 
other analyses of economic evaluations in this space.   
 Fiddelers et al., (2009) examined the cost-effectiveness of seven different IVF 
strategies that range from eSET with standard treatment to double embryo transfer (DET) 
with other conditions.  The authors utilized Markov decision models combined with 
probabilistic sensitivity analysis as well as Monte Carlo simulations to understand the 
gain in effectiveness of any one particular strategy.  The authors concluded that 
combining treatment strategies is not cost-effective, and that cumulative (up to three) 
cycles of IVF with eSET or DEP is equally cost-effective.  
 Cumulative IVF outcomes have also been examined through the lens of CEA.  A 
recent study sought to understand the cost-effectiveness of DEP versus cumulative IVF 
attempts with eSET.  The study was a retrospective analysis of previous data reported 
through NASS via the CDC.  The authors also utilized sensitivity analysis to analyze the 
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data to determine total costs of eSET versus DET.  They concluded that cumulative eSET 
for certain patients is a more cost-effective option than DET (Crawford et al., 2016). 
 Economic evaluations of ART and IVF are useful in estimating costs and 
obtaining meaningful cost estimates.  A study examined the overall costs and elasticity of 
ART for multiple first-world regions/countries, including Canada, USA, UK, 
Scandinavia, Japan, and Australia.  The review of overall costs for ART procedures in 
multiple countries revealed excellent cost data per live birth, where the United States had 
a cost per live birth with ART of $41,132 compared to $33,183 in Canada (2006 dollars)  
(Chambers, Sullivan, Ishihara, Chapman, & Adamson, 2009).   
CEA in IVF and PGS 
 There are multiple CEA studies that specifically involve PGS and IVF and the 
results and conclusions are mixed.  The first such study examined the cost-effectiveness 
of PGS #1 (FISH) in infertile women aged 38-40 and >40 undergoing one cycle of IVF 
with subsequent frozen cycles available to achieve a live birth.  The authors utilized a 
decision-analysis model to examine the live birth rates with each intervention.  They 
employed sensitivity analysis to determine which intervention provided the best costs per 
live birth.  The authors concluded that IVF alone was a far more cost-effective strategy 
than PGS with IVF in women aged 38-40.  For women aged 40 or older, they conclude 
that CEA is roughly equal between strategies (Mersereau et al., 2008).  The main 
limitation of this study is that they did not look at PGS#2 technologies where the clinical 
probabilities of a live birth have increased dramatically, and that costs over the past eight 
years have changed dramatically.  
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 A more recent economic study examined the cost-effectiveness of two 
interventions, IVF combined with PGS, and expectant management for patients with 
recurrent pregnancy loss.  Expectant management is a clinical strategy that allows the 
infertile couple to continue to attempt spontaneous natural conception without the use of 
ART.  The study used a CEA decision tree to examine the two strategies and used the 
clinical effectiveness of each strategy obtained from the literature, specifically the clinical 
live birth rate obtained from Hodes-Wertz et al. (2012) where PGS was performed on 287 
cycles of IVF for RPL patients.  The clinical live birth rate for expectant management 
was obtained from Brigham et al (1999) that looked at live birth rates from 325 patients 
with RPL that were treated with expectant management.  The study found that expectant 
management was a far more cost-effective strategy that IVF in conjunction with PGS for 
patients with RPL, regardless of age group (Murugappan et al., 2015).   
 A recent abstract from the American Society of Reproductive Medicine meeting 
concluded that PGS in a fresh transfer was not cost-effective compared to IVF alone in 
patients older than 39.  The analysis was made using previous data concerning false 
positive rates in PGS (Salem et al., 2016).  This was the first study to look at the 
influence of false positive rates on the cost-effectiveness of PGS and IVF. 
 Other studies conflict in their conclusions about PGS and IVF.  Recent studies 
have looked at retrospective data to determine the cost per live birth with IVF and PGS 
compared to IVF with fresh transfers and subsequent frozen transfers in different cohorts 
of women.  A single-center recent study by Hodes-Wertz, McCulloh, and Grifo (2015) 
examined retrospective data for patients using PGS and without PGS with routine IVF 
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from 2011-2013.  There were 1,910 patients total, with 1,133 undergoing routine IVF 
with subsequent FET  and 777 patients undergoing one cycle of PGS with IVF/ICSI.  The 
overall live birth rate without PGS was 24%, and the live birth rate with PGS was 52.5%.  
The authors used direct costs for IVF and PGS and found that PGS was cost-effective in 
all age groups but women over 42. 
 The conclusions of that study have been seen in other CEA analyses.  One recent 
abstract examined the cost-effectiveness of IVF with aCGH PGS compared to IVF alone 
for patients with RPL.  The authors concluded that it cost $19,416 to achieve a live birth 
with PGS, versus $23,184 with IVF alone.  These results were combined and the authors 
concluded that all age groups saw similar cost benefits  (Resetkova et al., 2013).   
 However, others have looked at similar retrospective data and determined that 
there is a bias in the selection of women with PGS, and that explains any increase in live 
birth rate.  They conclude that PGS with IVF is not a cost-effective strategy compared to 
IVF alone (Kushnir et al., 2016).  In almost all cases, the authors recommend further 
studies to understand the true cost-effectiveness of PGS in any IVF treatment strategy.   
 Of note is the wide variation in cost estimates to achieve a live birth from study to 
study.  Murugappan et al. (2015) reported a cost of $45,300 to achieve a live birth using 
PGS, whereas Resetkova et al (2013) reported a cost of $19,416 to achieve a live birth 
with PGS.  Hodes-Wertz, McCulloh, and Grifo (2015) found that costs per live birth 
varied by age group, with costs for women under 35 totaling $65,278, women aged 35-39 
of $65,841, women aged 40-42 of $89,350, and women aged over 42 of $291,907.  
Further, Chambers et al. (2009) reported a general cost per live birth of $41,132 in the 
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United States, where PGS or PGD costs were not considered.  These variations in 
estimates lead to the large gaps in understanding the true cost-effectiveness for PGS.    
Summary and Conclusions 
 The current literature associated with PGS and its impact on achieving a live birth 
via IVF reveals mixed conclusions where no consensus about its clinical utility has been 
reached (Orvieto, 2016).  Summarizing what is known and not known for PGS, the main 
issue is the fierce debate between researchers on both the clinical utility of PGS as well as 
the cost-effectiveness.  Concerning the clinical efficacy, the literature that does not 
include PGS#2 technology shows that PGS with IVF has a lower birth rate than with 
PGS, regardless of age.  However, the literature points to increased live birth rates, 
decreased miscarriage rates, and increased pregnancy rates for all age groups with the use 
of PGS, leading more and more clinicians to adopt routine PGS use in their clinical 
practice (Mastenbroek & Repping, 2014).  Further, most research agreed cumulative IVF 
attempts result in increased live birth rate in certain populations of patients.   
 The cost-effectiveness of using PGS with IVF is also not clear from the current 
literature.  It is also not clear if using PGS is effective in all age groups, or if age makes a 
difference in whether PGS is cost-effective or not.  Many studies show the benefit of 
using PGS in certain populations of patients, including all women under age 42 (Hodes-
Wertz et al., 2015; Resetkova et al., 2013).  Others have shown some cost-effectiveness 
in women but only in women aged 38-40, and not for older women (Mersereau et al., 
2008).  Other studies suggest that PGS is not cost-effective at all, regardless of age group 
(Kushnir et al., 2016).  And still most CEA studies involving PGS do not stratify the 
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results by age group, making it difficult to assess the impact age makes on the results 
(Murugappan et al., 2015).   
 Dahdouh et al. (2015) stated this about the gaps in the literature concerning CEA 
and PGS:   
The cost-effectiveness of CCS can be resolved only following cumulative live 
birth rates. NGS may represent the next frontier of PGS and has the potential to 
decrease costs. Any future study evaluating the cost-effectiveness of CCS versus 
standard care must take into account all available procedures and related cost. 
These aforementioned points need to be considered, but until such data become 
available, the debate continues on this crucial aspect of PGS. (p. 1509) 
Comparing cumulative live birth rates and IVF with PGS, along with understanding the 
variance associated with age group, is the next step to understanding the usefulness of 
PGS in the clinic, and it is what this study hopes to achieve.    
 This study seeks to continue to enhance the community’s understanding of 
whether PGS with IVF in one cycle is cost-effective compared to going through multiple, 
cumulative cycles of IVF without PGS, and whether age makes a difference in that cost-
effectiveness.  While there are some recent studies that examined the cost-effectiveness 
of PGS based on retrospective data, but none to date have examined IVF with PGS in one 
cycle compared to achieving a live birth if a patient goes through three consecutive cycles 
of IVF without PGS.    
 Chapter 3 will include a description of the methodology of this study.  Further, it 
will include the rationale for the design of the study and the methods used to analyze the 
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results.  It will describe the model used for this study and the analytics used to determine 
the results of the study including any threats to validity. Lastly I will examine what costs 
will be included for each intervention and their source.   
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Chapter 3: Research Method 
The purpose of this study was to compare the cost effectiveness of two 
interventions using secondary data to determine the best economic outcome based on 
limited resources.  The two interventions are IVF utilizing PGS and cumulative, 
consecutive cycles of IVF without PGS.  The clinical outcome is a live birth (defined as a 
singleton or multiple birth after 24 weeks of gestation that survived at least one month) 
and was stratified by age group.  In this chapter, I will discuss the research design and 
methodology and as well as the rationale for the approach.  The components involved in 
the costs of each intervention are also discussed, along with any threats to validity.  
Lastly, I will explore any ethical considerations with this research design.   
Research Design and Rationale 
The research design of this study was a cross-sectional, quantitative, economic 
modelling design using secondary sources.  The independent variables in this study were 
the method of treatment, either one cycle of IVF with PGS (IVF-PGS) or three 
consecutive, cumulative cycles of IVF (3xIVF).  The dependent variable was cost, or 
cost-effectiveness as determined by an incremental cost-effectiveness ratio (ICER) of 
costs per live birth.  In order to study the effect of each intervention on cost-effectiveness, 
a theoretical decision-analytical model—in this case, a cost-effectiveness health model—
was created using TreeAge Pro 2017 (www.treeage.com).  The conceptual strategy was 
for the cost-effectiveness of two interventions to be compared using the model.  
The rationale for using a cost-effectiveness model was that the vast majority of 
CEA in healthcare utilized a decision-analysis tool to determine the best path forward 
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between two or more interventions.  Prior CEAs studies that have involved PGS and IVF 
have been conducted using a decision-analytical model or Markov model to understand 
how each intervention compares to another (Hodes-Wertz, McCulloh, & Grifo, 2015; 
Murugappan et al., 2015). 
A cost-effectiveness model is theoretical, and does not limit the researcher based 
on any time or resource constraint other than collecting the relevant data, building the 
model, and analyzing the results.  Statistical analysis for this research design included 
sensitivity analyses, probabilistic sensitivity analysis (PSA), and Monte Carlo 
simulations.  More details on each statistical method and interpretation are in the data 
analysis section.    
 To explore the research questions, I compared each intervention via a decision-
analytical model.  First, the model allowed for direct comparison of cost-effectiveness for 
each intervention.  Second, by stratifying the analysis by age group, I clearly illuminated 
any differences due to the age of the patient.  I explain the methodology and assumptions 
made in the model in the next section.   
Methodology 
Population and Sampling 
 The population for the model was any infertile couple seeking treatment from an 
IVF clinic and data was from secondary sources.  Many of the seminal works for PGS 
and clinical effectiveness in delivering a live birth have been prospective trials in which 
researchers looked at embryos compared to live births (Hodes-Wertz, Grifo, Ghadir, 
Kaplan, & Laskin, 2012).  Researchers who conducted one cost-effectiveness study on 
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PGS in RPL patients used studies from the literature in order to determine the live-birth 
rates for each arm of the decision matrix (Murugappan et al., 2015).  In that particular 
study, researchers compared the IVF with PGS of 287 cycles of IVF results with the 
expectant management results from 325 patients from a longitudinal study by Brigham et 
al (1999).  Many CEAs are not prospective trials and used the literature to determine the 
outcomes of the decision arms (Garber & Phelps, 1997).   
For this study, sample size needed to be determined for each arm.  Three factors 
influence the sample size: the Effect Size, the Power, and the Alpha Level (or 
significance level).  Knowing these three factors will allow a researcher to calculate the 
fourth.  Effect Size is the importance of the treatment against the background of noise in 
the measurement.  Power refers to the probability that you will observe an effect of 
treatment when there really is one.  Lastly, the Alpha Level is the probability that the 
observed result is due to chance (Trochim, 2006).   
Ideally, an equal number of participants should be in both arms, and because 
retrospective data collected from the CDC and other studies is being used, there will be 
some finite number of participants.  Generally, a large power variable is preferable, and a 
smaller alpha variable when the chances of making a Type I error are too great.  Effect 
size was based on the treatments available for both arms. In this study, because I was 
studying the effects out to a similar outcome (live birth) for both arms, then the Effect 
Size needed to be .5, indicating that I believed the treatment to result in a live birth for 
both arms.    
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However, because the samples from the literature are set, they were more likely to 
have to calculate the effect size from the sample set.  Given the samples from other CEA 
studies of 250 patients, an effect size of .5, and an alpha of .05, a G*Power analysis 
provided a power of .99, which indicated that at least 250 patients in each arm was more 
than statistically significant enough to avoid Type I errors.  Both interventions had more 
than 250 participants.  Understanding the inputs for each intervention strategy determined 
the number of patients examined in each arm.   
Intervention Strategies 
The basic cost-effectiveness decision model is shown in Figure 2.  For the 
consecutive cycle strategy (3xIVF), the model assumed that each patient underwent an 
IVF cycle without using PGS to screen for ploidy.  In this strategy, a cycle is defined as 
any number of embryo transfers from a single given oocyte retrieval event.  The model 
assumed that each cycle included one fresh and one FET.  The model also assumed that 
all patients used their own oocytes, and no donor eggs were used.  The possible outcomes 
of the first cycle were no pregnancy, clinical miscarriage, or live birth.  If the patient did 
not have a live birth, they would move to the second theoretical cycle, where the possible 
outcomes were the same as the first cycle.  Again, if no live birth, then the patient would 
move to a third cycle, where the possible outcomes were the same as the other two 
cycles.  The model assumed that no patients dropped out between cycles, despite 
evidence that large number of patients do dropout between cycles (Luke et al., 2012).  
The decision tree ends at that point.  
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For the IVF-PGS strategy, the model assumed that every patient had at least one 
euploid embryo.  At that point, each patient underwent IVF followed by a FET (no fresh 
transfer).  The possible outcomes were no pregnancy, clinical miscarriage, or a live birth.  
The model did not make assumptions about the number of embryos transferred in this one 
cycle.  For costs, both interventions assume that ICSI was employed for each cycle, with 
or without PGS. 
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Figure 2.  Simplified decision tree showing the two interventions, IVF with PGS and 
three consecutive cycles of IVF.   
 
Clinical Probabilities 
 For each node of the model, there was an assumption based on the clinical 
probability of each possible outcome.  For these statistical rates, I utilized published 
literature and recent studies to determine the outcome.  
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 Cumulative (3xIVF) strategy.  For the consecutive, cumulative IVF strategy 
(3xIVF), the probability rates were taken from the groundbreaking study on cumulative 
IVF and live birth rates by (Smith et al., 2015).  In this study, the authors examined 
257,655 cycles of IVF that were performed on 157,475 women in the United Kingdom 
between the years of 2003 and 2012.  They excluded any women who had previously had 
a live birth from ART, or had started IVF prior to 2003.  They also excluded any cycles 
that were not started exclusively for the purpose of achieving a live birth.  This is the 
largest retrospective study to date that links multiple cycles of IVF with live birth rates 
(Smith et al., 2015).    
 Smith et al. (2015) were able to determine live birth rate in each individual cycle 
and infer cumulative live birth rates up to nine cycles of IVF.  Further, the study was able 
to stratify these findings by age group for women under the age of 40, aged 40-42, and 
older than 43.  The authors utilized three assumption strategies to deal with women who 
dropped out between each consecutive cycle. First, they calculated cumulative live birth 
rates and assumed that every woman that dropped out would have had the same rate of 
live birth as those that stayed in, known as the “optimal estimate”.  Second, they assumed 
that 30% of the women that dropped out would have not achieved a live birth, known as 
the “prognostic-adjusted estimate”. Lastly, they assumed that no woman that dropped out 
would have achieved a live birth, known as the “conservative estimate”.  For the purposes 
of this study, we assumed no participants dropped out between cycles and used the 
optimal estimate.    
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 Another critical element to determine costs associated with each intervention is 
pregnancy rate and miscarriage rate.  For the 3xIVF strategy, pregnancy rates from the 
2014 CDC survey data was used for each age group.  Because the CDC stratifies ages for 
each two year block as well as by frozen or fresh transfer, I averaged the pregnancy rates 
for all women under the age of 40 regardless of transfer method.  I then calculated 
miscarriage rates by subtracting the 1st cycle live birth rate obtained from the Smith et al. 
(2015) study from the pregnancy rate published by the CDC (“ART Success Rates (ART) 
Data | Reproductive Health | CDC,” n.d.).  If the outcome was not a miscarriage or a live 
birth, then it was assumed to be a no pregnancy.  See Chapter 4 for values.   
Live birth rates for IVF-PGS.  The clinical success rates from the literature for 
utilizing PGS in one cycle of IVF have ranged from 35% to 85%, depending on the study 
and the methods used (Chen et al., 2015).  In their CEA analysis of IVF with PGS 
compared to expectant management for patients with recurrent pregnancy loss, 
Murugappan et al. (2015) utilized the clinical rates established by Hodes-Wertz, et al 
(2012) where PGS was performed on 287 cycles of IVF for RPL patients.  That live birth 
rate in that study was 40% with a calculated miscarriage rate of 7%.  However, these 
rates were not stratified by age group and so are difficult to apply to this study. 
 A more recent study stratified live birth rates for IVF with PGS by age group, and 
fell within the range of live birth rates established in other studies, but not does not reveal 
pregnancy rates or miscarriage rates (Hodes-Wertz et al., 2015).  Another recent study by 
Salem, et al (2016) provides clinical miscarriage rates for patients in the same age groups, 
and are similar to the calculated miscarriage rates used by Murugappan et al (2015).  This 
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study utilized these rates and for clinical probabilities used in the model, and are shown 
in Chapter 4.   
Costs 
 The most important aspect of any CEA is what costs are associated with the 
analysis (Meltzer, 2001).  For infertility treatment studies, accurate and consistent values 
for costs remain a difficult variable to ascertain and remain one of the fields most 
challenging topics (ESHRE Capri Workshop Group, 2015).  Each CEA that involves 
PGS has used slightly different costs, but most recent analyses utilize direct costs to the 
patient associated with IVF, PGS, miscarriage, and births.   
 Recent studies involving PGS have identified the minimal costs that need to be 
associated with any PGS-related cost-effectiveness study.  From Dahdouh (2015), 
Any future study evaluating the cost-effectiveness of CCS versus standard care 
must take into account all available procedures and related costs. These should 
include, at minimum, the costs of the following techniques: the IVF cycle, the 
CCS analysis, the first fresh embryo transfer and all subsequent frozen transfers, 
the obstetrical care, and any additional prenatal care provided to ongoing 
aneuploid gestations, from pregnancy time until delivery. (p. 1509)  
 Hodes-Wertz et al. (2015) identified the costs associated with their recent PGS 
cost-effectiveness, and it included costs for 
…routine IVF cycle with and without embryo transfer, FET of unscreened and 
euploid embryos, IVF with PGS (including shipping of specimen, outside 
laboratory cost to run specimen, and cryopreservation of embryos) with and 
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without transfer, dilation and curettage performed on early pregnancy failure, 
termination of pregnancy, laparoscopic salpingectomy per-formed for ectopic 
pregnancy, livebirth of singleton, twins, and triplets. (p.p505) 
This study will include the direct costs for both strategies as defined above by 
Hodes-Wertz et al. (2015). However, because both strategies have an outcome of cost per 
live birth, we can assume that obstetrical care (costs for live birth obstetrical care) are 
equal in both strategies, and therefore can be excluded. The costs used in this study are 
detailed here: 
• Procedure Costs (PC), including: 
o Routine IVF Cycle 
o Oocyte retrieval 
o Medications costs 
o ICSI 
• Fresh Embryo Transfer (FT) 
• Frozen Embryo Transfer (FET) 
• PGS Costs (PGS) (includes procedure, shipping, and reporting) 
• Clinical Dilation and Curettage (D&C) associated with miscarriage 
The other issue facing researchers is the source of the costs associated with these 
procedures.  This study used the perspective of the payer, in this case, the patient, to 
estimate costs.  There are multiple studies that highlight the costs used for each kind of 
procedure.  To attempt to normalize the variation in costs and methods from study to 
study, we averaged multiple studies’ cost estimates, along with costs obtained with 
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permission from one established IVF clinics in the United States.  See the section on 
Archival Data for more information on the sources for data used in this study.   
I assumed that for the 3xIVF arm, there was one fresh embryo transfer and one 
FET per cycle.  For the IVF-PGS arm, I assumed only one FET, as I assumed that all 
PGS procedures would be trophectoderm biopsies followed by a “freeze all” strategy 
(Maxwell et al., 2015).  Further, I assumed that patients incurred the full cost of three 
cycles of IVF in 3xIVF strategy, and that costs for multiple cycles will be calculated per 
cycle. In other words, each cycle of IVF was assumed to incur the same costs as any 
other cycle (more discussion about the advent of discounted multi-cycle plans in the IVF 
community can be found in the Chapter 5).   
Archival Data 
 I used secondary data from a combination of public domain and from individual 
clinics for clinical probabilities and costs.  The sources of this data included data 
available from the literature, clinic websites, by permission from one private clinic, and 
from public databases maintained by the CDC. Data obtained from the literature are cited 
and any additional data obtained from the authors were retrieved by permission from the 
authors.  Clinical data was retrieved from the CDC database. Costs were obtained from 
the literature as well as from one private clinic.  The private clinic is located in New York 
City and performs over 2,300 cycles of IVF per year (“ART Success Rates (ART) Data | 
Reproductive Health | CDC,” n.d.).  The data for this clinic was obtained via permission 
and all data was de-identified of all personal health information (PHI).  See Appendix B 
for the data use agreement letter. 
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 The CDC maintains a database of data obtained from all clinics in the United 
States that perform ART.  This data is updated annually and is typically two years aged 
from the current year due to the length of time for pregnancy.  The data can be 
downloaded without permission at https://www.cdc.gov/art/artdata/index.html and results 
are delivered as an excel spreadsheet.  They are also reported in a comprehensive report 
funded by the CDC (Sunderam et al., 2015).  Specific costs, their sources, and the mean 
costs are detailed in Chapter 4.    
Data Analysis Plan 
 All statistical analysis was performed in TreeAge Pro 17 and Microsoft Excel.  
Statistical practices include confidence interval determination via bootstrapping, z tests, 
one-way sensitivity analyses, probabilistic sensitivity analysis (PSA) via Monte Carlo 
simulations.  A description of each statistical practice and the data analysis plan for each 
research question is listed below. 
 Confidence Intervals / z-test for ICER.  Determining the confidence interval for 
an ICER is not trivial, as the ICER is a ratio and the uncertainly around the point estimate 
can vary based on either the change in costs or change in effects.  Many methods for 
determining the confidence intervals from the ICER have been discussed in the literature. 
I used a bootstrapping method where 1000 resamples of the analysis are performed and 
then the 97.5% and 2.5% brackets are translated to the 95% confidence intervals.  This 
technique has held up as a good way to estimate the ICER for a CEA (Ming-Yu & Xiao-
Hua, 2007). 
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 The analysis of bootstrapping also provides standard deviations.  Assuming that 
the distribution for the ICER is normal, and with a known standard deviation, a z-score 
and p-value for significance can be used to test the hypotheses (Altman & Bland, 2011). 
 One-way sensitivity analysis.  One-way sensitivity analysis, or univariate 
sensitivity analysis, is a form of deterministic sensitivity analysis and is a way to 
determine how the uncertainty of the model inputs affects the model outputs by changing 
one variable at a time and examining the results compared to the base case.  This kind of 
analysis is useful to determine the impact of any one variable on the outcome of the study 
(Andronis, Barton, & Bryan, 2009). 
 Probabilistic sensitivity analysis.  Probabilistic sensitivity analysis (PSA) is a 
way to look at multiple variables in the model all at once by assigning a distribution to 
each parameter and drawing a random value over multiple simulations.  PSA is useful to 
test the robustness of a model over a wide range of possibilities (Andronis et al., 2009). 
 Monte Carlo simulations. Monte Carlo simulations are useful for normalizing 
variation by looking at many factors whose outcomes are uncertain, and may be run in 
parallel with PSA.  These mathematical, computer-driven simulations are used frequently 
when groups of patients are being compared to each other versus individual patients 
(Halpern, Weinstein, Hunink, & Gazelle, 2000).  Using this kind of analysis is consistent 
with current literature on the topic, and will allow for comparison of this study to others 
to help advance the knowledgebase of this area or research.   
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Research Question 1.  What is the cost-effectiveness of IVF paired with PGS in 
one cycle compared to three consecutive cycles of IVF in achieving a similar live birth 
rate? 
Null Hypothesis (H01):  There was no statistically significant difference in the 
cost-effectiveness of proceeding to three cycles of IVF without PGS in achieving a live 
birth than one cycle of IVF with PGS.  This hypothesis will be tested using a z-test for 
comparison.  If p<.05 for the z-test for the ICER, then the null hypothesis will be rejected 
and the alternate hypothesis will be accepted.     
Alternative Hypothesis (H11):  There was a statistically significant difference in 
cost-effectiveness in utilizing one cycle of IVF with PGS in achieving a live birth than 
three cycles of IVF. 
The main outcome of the data analysis was the cost-effectiveness ratio (CER) of 
each intervention, which is the cost per live birth.  In order to make this calculation, the 
total costs involved with one cycle of IVF were determined: 
Total Single Cycle Costs (TSCC) = Procedure Costs (PC) + Fresh Embryo 
Transfer Costs (FT) + Frozen Embryo Transfer Costs (FET) + Dilation and 
Curettage Costs (D&C) + Preimplantation Genetic Screening Costs (PGS) 
D&C costs are only applied if the outcome is a clinical miscarriage.  For the IVF-PGS 
intervention, the CER of costs per live birth was calculated as: 
  
CER = TSCC / Clinical probability of live birth using PGS (LB_CP_PGS) 
For the 3xIVF intervention, the CER was calculated as: 
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CER = (3x(TSCC-PGS)) / Clinical probability of live birth at 3rd cycle 
(LB_CP_IVF3) 
The research question was answered by comparing the two cost-effectiveness ratios and 
determining which intervention provided the same clinical outcome for the least cost, 
also known as the Incremental Cost Effectiveness Ratio (ICER).  This was calculated as 
the difference in total costs between strategies divided by the difference in live birth rates 
between the two strategies.  For the  ICER, 95% confidence intervals and variability 
around the ICER were reported from the simulations as per best modelling practices 
(Briggs et al., 2012).  Z-statistics were calculated from the confidence intervals along 
with p-values for significance.  The formula for this is: 
ICER = C2 – C1 / E2- E1 
Where C2 = Total costs of IVF-PGS 
C1 = Total costs of IVFx3 
E2 = Clinical probability of a live birth for IVF-PGS 
E1 = Clinical probability of a live birth for IVFx3 
 A series of univariate sensitivity analyses was performed to test the impact of 
different variables.  First, the clinical probabilities for live birth for each intervention 
were modelled with a value of ±25% of each branch of baseline value (women under age 
40).  Secondly, costs were also varied from ±25% of baseline value for each branch.  
Results were reported in tabular form and presented as a Tornado graph.   
 To resolve parameter uncertainty, PSA was performed using a distribution for 
clinical probabilities and costs.  Distribution for each variable was determined to be 
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Dirichlet distribution for clinical probabilities and a lognormal distribution for costs.  
Further, 1000 Monte Carlo simulations were used to validate the analysis over multiple 
scenarios.    
Research Question 2.  What are the statistical differences between cost-
effectiveness among three different age groups of women in each treatment arm?   
Null Hypothesis (H02):  There was no statistically significant difference based on 
z-test in the cost-effectiveness of between three different age groups of women using 
either intervention.  
Alternative Hypothesis (H12):  There was a statistically significant difference 
based on a z-test in cost-effectiveness in one or more age groups using one or the other 
intervention.   
Similar to the first research question, we examined the CER for each intervention 
stratified by age group.  We then applied confidence intervals for each group’s ICER and 
determined the z test and p value for significance.  If the p value for any one of the age 
group’s ICER is < .05, we can accept the alternate hypothesis and reject the null. The age 
groups were 
• Women aged less than 40 
• Women aged 40-42 
• Women aged older than 42 
The CER for each age group and each intervention provided six unique CERs, 
which were calculated in the same manner as described for research question #1.  We 
then compared CERs by age group and intervention to determine the incremental cost 
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effectiveness ratios.  We applied the same statistical tests used for the first research 
question, including univariate sensitivity analysis adjusting for live birth probability and 
costs.  We also ran Monte Carlo simulations with PSA over 1000 iterations to determine 
the robustness of the model.       
 Other secondary analysis points include a willingness-to-pay (WTP) threshold 
defined as $100,000 per QALY, or in this case, per live birth.  A WTP threshold is a 
benchmark used in CEA to determine a society’s willingness to pay for improvements in 
health.  It was previously set as $50,000 per QALY, based on years-old analysis of one 
aspect of healthcare.  However, many have argued that $100,000 per QALY is an 
appropriate benchmark for today’s CEA and that benchmark has been used in recent 
CEA involving IVF and PGS (Murugappan et al., 2015; Neumann, Cohen, & Weinstein, 
2014).  By defining the benchmark, the most effective intervention were compared to 
others using a similar yardstick.   
Threats to Validity 
 The validity of cost-effectiveness models in intervention-based studies has been 
examined.  O’Brien (1996) identified seven major threats to validity in CEA studies 
involving multiple interventions or head-to-head comparisons.  These are still applicable 
today, and are relevant to this study. Table 3 describes each threat and the mitigation of 
those threats in this study.  
Table 3 
Threats and Mitigation 
Threata Threat 
descriptiona  
Mitigation  
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Choice of comparison 
therapy  
Ensuring that all available 
therapies are evaluated 
The two interventions were 
determined by the gap in the 
literature and need for the analysis 
 
Gold standard 
measurement of 
outcomes.   
Some clinical trial do not 
allow for real-world clinical 
care outcomes 
For IVF studies, live birth as the 
main clinical outcome ensures this is 
not a threat.  
 
Intermediate rather 
than final health 
outcomes  
 
Outcomes evaluated at a mid-
point in the care continuum 
As live birth is the main clinical 
outcome, this mitigates the threat.   
 
Inadequate patient 
follow-up or sample 
size 
 
Some clinical trials do not 
follow the patient through to 
the final outcome and miss 
certain economic factors 
Sample size is adequate, as described 
elsewhere in this chapter.  Further, 
costs associated with adverse events, 
such as miscarriage, were taken into 
account.   
 
Protocol-driven costs 
and outcomes  
 
Clinical trials where protocol 
specific costs are incurred 
All costs associated in this study are 
from the regular routine treatment of 
patients, and not some specific 
protocol.   
 
Geographical 
transferability of trial 
evidence 
Costs and clinical care differ 
in various parts of the country 
and need to be assessed 
Geographic differences in prices 
were mitigated through using cost 
data from multiple sources in 
different locations across the 
country.   
   
Selected patient and 
provider populations 
Hand-picking patient 
populations and thereby bias 
the study 
By utilizing the literature and 
multiple sites for cost data, patient 
and provider populations were 
adequately managed.   
   
a.From “Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of 
trials? ” O’Brien, B. 1996. Medical Care, 34(12 Suppl), DS99-108.  
             
 Further threats to validity are detailed in the recent International Society For 
Pharmacoeconomics and Outcomes Research Task Force update to recommendations 
(Ramsey et al., 2005), originally published in 2005.  The task force relayed five major 
threats to validity when using data driven by clinical trials or other studies.  They include 
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protocol-driven resource use, comparators that are uncommon or not recommended in 
clinical practice, non-representative recruiting, restrictive inclusion and exclusion criteria, 
and artificially enhanced compliance (Ramsey et al., 2015).  
Of these threats, this study is particularly susceptible to recruiting issues between 
interventions.  The cumulative (3xIVF) arm uses over 150,000 women in determining the 
live birth rate, whereas the IVF-PGS arm used just over 1,900 women in the studies used 
to determine clinical effectiveness.  However, because the sample size calculations are 
statistically significant, this threat is generally very low.   
Ethical Considerations 
 Ethical considerations in any research study are essential to ensure no harm comes 
from the research itself.  In this case, no human participants were directly used to 
determine any portion of the analysis.  Further, all cost data from private clinics were 
obtained by permission using Data Use Agreements (DUA) that strictly define the data 
use and sources.  The DUA ensure that no Personal Health Information (PHI) was used or 
revealed and also ensures that the research collaboration between the sources and users of 
the data do not breach any part of the Health Information Portability and Accountability 
Act (HIPAA) statutes.  The study was reviewed and approved by Walden university 
Institutional Review Board – approval number 07 26 17 044 33 96. 
Summary 
 The study design was a CEA using a decision-analytical tool to model a 
theoretical interventional comparison using secondary data sources.  The two 
interventions studied are patients that undergo IVF in conjunction with PGS for one cycle 
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versus patients that undergo three consecutive cycles of IVF without PGS.  For each 
intervention, costs and clinical probabilities at each node were used.  For costs, multiple 
sources from the recent literature and two independent IVF clinics were used to 
determine direct costs.  For clinical probabilities, the literature was used to determine the 
most relevant clinical probabilities of each intervention.  The sample size from the 
literature and costs set were robust enough to avoid sampling errors.  A benchmark of 
$100,000 per live birth was used as the willingness-to-pay threshold for comparison 
purposes.   
 All CEAs are vulnerable to threats to validity, mainly from the sources of the data 
and the variables examined.  Most of these threats were mitigated through careful 
examination of the material and using multiple sources of data.  Because the model is 
theoretical, no human participants were used and therefore ethical considerations were at 
a minimum.  All actual data from clinics were de-identified of all personal health 
information before used in the research.   
 Chapter 4 will involve a description of the findings of the study.  It will include 
the statistical results and describe the data that was included in the analysis.  It will also 
present information related to each arm of the decision model.   
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Chapter 4: Results  
Introduction 
The purpose of the study was to examine two interventions in IVF and determine 
the cost-effectiveness of each in achieving a live birth.  The two interventions were IVF 
using PGS in one cycle, and the other was three, consecutive cycles of IVF. The first 
research question was whether there was a statistical difference in the cost-effectiveness 
ratios of each intervention.  The second was whether there were statistical differences by 
age group, specifically women under age 40, women aged 40-42, and women aged over 
42.  I hypothesized that there was a statistical difference overall for one cycle of IVF with 
PGS versus three cycles of IVF.   
In Chapter 4, I will present the data collection methods and the values used for 
both costs and clinical probabilities in the cost-effectiveness model.  Further, I will 
explain the statistical methods used to analyze the data and test the robustness of the 
model.  Lastly, the results of the model will be presented.   
Data Collection 
 The key secondary datasets used in this study were costs and clinical 
probabilities.  I obtained clinical probabilities from two sources.  The first source was the 
published literature, and the second source was from publicly available datasets provided 
free of charge by the CDC and fertility clinic websites.  Concerning costs, secondary data 
sets used were from multiple sources, including the literature, public sources, and from 
one private clinic.  The next three tables detail the percentages used and the literature 
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sources used in the model.  Table 4 details the clinical probabilities for cumulative live 
births.   
Table 4 
Cumulative Live Birth Rate Probabilities by Age, Prognostic-adjusted Estimate (%) 
Cycle Women aged < 40 years Women aged 40-42 Women aged > 42 
1st Cycle 32.3 12.3 3.7 
2nd Cycle 48.7 19.8 6.3 
3rd Cycle 58.0 24.7 8.3 
Note. Adapted from “Live-Birth Rate Associated with Repeat In Vitro Fertilization 
Treatment Cycles,” by Smith et al., 2015, Journal of the American Medical Association, 
98, p. 2659.  
 
Table 5 describes the clinical probabilities of pregnancy, live birth, and 
miscarriage used in the final model for the 3xIVF intervention arm, stratified by age 
group. The calculation of the averages were described in detail in Chapter 3.    
Table 5 
Pregnancy, Live Birth, and Calculated Miscarriage Rates by Age, (%) 
Rates Women aged < 40 
years 
Women aged 40-42 Women aged > 42 
Pregnancy ratea 50.3 35.6 20 
    
1st Cycle live birth rateb 32.3 12.3 3.7 
2nd Cycle live birth rateb 27.1 10.1 3.3 
3rd Cycle live birth rateb 24.3 8.6 3.3 
1st Cycle miscarriage ratec 18.0 23.3 16.3 
2nd Cycle miscarriage ratec 23.2 25.5 16.7 
3rd Cycle miscarriage ratec 26.0 27.0 16.7 
a Averaged for all ages and transfer type, from Centers for Disease Control and 
Prevention, ART Clinical Success Rates, 2016, p. 21.  bFrom “Live-Birth Rate 
Associated with Repeat In Vitro Fertilization Treatment Cycles,” by Smith et al., 2015, 
Journal of the American Medical Association, 98, p. 2659. cCalculated.  
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 Table 6 describes the pregnancy rates, live birth rates, and miscarriage rates as 
used in the CEA models for the IVF-PGS intervention.  Again, the description of the 
calculations are detailed in Chapter 3.   
Table 6 
Pregnancy, Miscarriage, and Live Birth Rate Probabilities by Age with PGS, (%) 
 Women aged < 40 
years 
Women aged 40-42 Women aged > 
42 
Pregnancy ratea 82.0 47.8 28.1 
Live Birth rateb 63.2 33.3 8.1 
Miscarriage ratec 18.8 14.5 20 
Notes: aCalculated. bAveraged for women aged less than 40, from “Preimplantation 
Genetic Screening is cost-effective in cost per delivery compared to routine in vitro 
fertilization.” B. Hodes-Wertz, D. H. McCulloh, & J. Grifo. 2015. Fertility and Sterility, 
104, vol. 3, p.e278.  cFrom “IVF patients over age 39 experience decreased cost 
effectiveness and live birth rates with preimplantation genetic screening: a decision 
analytic model and cost effectiveness analysis,” by Salem et al., 2016, Fertility and 
Sterility, 106, vol. 3, p.e61.  
 
Table 7 details the costs used in the model by cost type.  Costs were derived from 
secondary sources, including the literature, one private clinic, and public websites. 
Table 7 
Costs per procedure, in 2016 US Dollars ($) 
Cost description Mean Standard 
Deviation 
Minimum 
 
Maximum 95% CI 
Routine IVF cycle (includes oocyte 
retrieval, ICSI, and fresh embryo 
transfer, and cycle medications) 
 
20,548 3,817 17,755 26,058 16,807-
24288 
Frozen embryo transfer 
 
5,108 983 4,000 6,395 4,145-
6,072 
PGS costs (includes procedure, 
shipping, and reporting) 
4,836 1,224 3,450 6,225 3,637-
6,035 
Clinical dilation and curettage 
(D&C) associated with miscarriage 
2,517 1,679 1,304 5,000 872 - 
4,163 
Notes: Costs obtained from Murugappan et al., 2015, Private Clinic by permission, and 
public websites.   
 
69 
 
Results 
Two research questions were asked: 
RQ1-Quantitative: What is the cost-effectiveness of IVF paired with PGS in one 
cycle compared to three consecutive cycles of IVF in achieving a live birth? 
The incremental cost-effectiveness for all women was ($2,657,388), with a 
confidence interval of ($3,087,000) – ($1,958,045), p < .05.  A negative ICER indicates 
that IVF-PGS is the preferred strategy across all age groups.  The CI does not include the 
null ($0), and the p value is less than .05 for the z test, and therefore the null hypothesis 
can be rejected and the alternate is accepted.   
RQ2-Quantitative: What are the statistical differences in means between cost-
effectiveness among women aged under 40, women aged 40-42, and women aged over 
40 of women in each treatment arm?   
For each age group, the ICER was examined and confidence intervals determined.  
The z score for each age group and p value was determined.  The results of the initial 
CEA are that in the age groups of women aged under 40, and aged 40-42, the IVF-PGS 
strategy dominated the IVFx3 strategy for cost-effectiveness.  However, neither strategy 
was dominant for women aged over 42.  Concerning RQ2, there were significant (p < 
.05) statistical differences between age groups for ICER, and therefore we can reject the 
null hypothesis and accept the alternate hypotheses.  The results show that IVF with PGS 
was a more cost-effective strategy for all age groups except for women over 42.  Table 8 
details the costs per live birth and ICERs per age group and strategy.   
70 
 
Table 8 
Cost per Live Birth per Strategy, Age Group, and ICER ($) 
 All ages Women aged < 40 
years 
Women aged 40-
42 
Women aged > 42 
IVFx3 366,630.41 90,770.30 250,799.64 758,321.30 
IVF-PGS 174,770.57 48,995.85 92,662.17 382,653.70 
ICER -2,657,388 -4,620,123.31 -731,317.69 2,402,310.35 
ICER 95% CI -3,087,000 –     -
1,958,045 
-9,405,548-        -
1,427,930 
-813,727 -        -
611,649 
2,252,176 – 
2,683,557 
Z score -9.22 -2.27 -14.19 -21.83 
One-tailed p value .00001 .012 .00001 .00001 
 
Cost-effectiveness graphs were plotted against the willingness-to-pay threshold 
for each age group. These graphs plot the costs per strategy against the effectiveness. If 
two strategies are undominated (or in other words, neither is preferred or more cost-
effective), then those strategies are connected by line segments which form the cost-
effective frontier. Only the strategies on the cost-effective frontier could be the optimal 
choice. The lowest cost option is always part of this frontier; if it dominates all 
comparators, the graph will have no lines.  This is the case for the first two age groups. 
The willingness-to-pay slope intersects with the favored strategy. For each scenario, the 
graphs plot which strategy was undominated, or preferred strategy compared to the 
dominated strategy.  Figures 3, 4, and 5 show the results of each.   
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Figure 3.  Cost v. effectiveness for women aged under 40 in achieving a live birth. 
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Figure 4.  Cost v. effectiveness for women aged 40-42 in achieving a live birth. 
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Figure 5.  Cost v. effectiveness for women over 42 in achieving a live birth. 
 
Univariate Analysis 
Univariate analysis was performed from baseline to examine the effect of live 
birth rate and cost by strategy.  The baseline model was women aged under 40.  Live 
birth rate was varied by + or – 25% for each branch, and then ICERs were re-examined.  
Further, costs were varied by the same amount for each branch to determine effect of the 
variation.  Results are shown in Figure 6 as a tornado diagram, where the expected value 
is the base case ICER of women aged under 40.     
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Figure 6. Tornado Diagram of univariate sensitivity analysis. Notes: 
LB_CP_IVF3 – Live birth probability in the third cycle 
LB_CP_IVF2 – Live birth probability in the second cycle 
LB_CP_IVF1 – Live birth probability in the first cycle 
LB_CP_PGS – Live birth probability in one cycle with PGS 
Costs_LB_PGS – Costs to achieve a live birth in one cycle with PGS 
Costs_LB_IVF1 – Costs to achieve a live birth in first cycle 
Costs_NP_LB_IVF2 – Costs to achieve a live birth in the second cycle of IVF 
where the first cycle resulted in a no pregnancy 
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Costs_NP_NP_LB_IVF3 – Costs to achieve a live birth in the thirs IVF cycle 
where the first two cycles both resulted in no pregnancies 
Costs_CM_LB_IVF2 – Costs to achieve a live birth in the second cycle where the 
first cycle resulted in a clinical miscarriage 
Costs_NP_CM_LB_IVF3 – Costs to achieve a live birth in the third cycle where 
the first cycle resulted in a no pregnancy and the second cycle resulted in a 
clinical miscarriage 
Costs_CM_NP_LB_IVF – Costs to achieve a live birth in the third cycle where 
the first cycle resulted in a clinical miscarriage and the second cycle resulted in a 
no pregnancy 
 The results of the univariate analysis show that the clinical probabilities have the 
largest effect on ICER, starting with the clinical probability of a live birth in cycle 
number 3 for the IVFx3 strategy.  Costs, however, did not have a considerable impact on 
the expected value.   
PSA / Monte Carlo Simulations 
Secondary analysis of each model for each age group included Monte Carlo 
simulations (PSA) to determine the robustness of the model.  A Dirichlet distribution was 
used for the clinical probabilities (to achieve a sum of .1000 for the three branches), and a 
lognormal distribution was used to model the costs using the mean and median.  1000 
simulations were run yielding a mean of each model that was within one standard 
deviation of the original model.   
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The statistics for each age group are shown in Table 9.  For the first two age 
groups, the IVF-PGS strategy dominated at a WTP of $100,000 and was dominant for 
women aged 40-42 in all scenarios.  However, for women aged under 40, and as WTP 
increases, the model shows that IVFx3 could begin to become a preferred strategy, with 
preference defined as the most cost-effective strategy in the majority of iterations.  Even 
at a WTP of $3M, IVF-PGS was the preferred strategy 76% of the time (see Figure 7). 
For women over 42, IVF-PGS was the dominant strategy at a willingness-to-pay 
of $100,000.  In other words, if $100,000 is the amount one was willing to pay to achieve 
a live birth and could not spend over that amount, then IVF-PGS would give you the best 
probability to achieve a live birth.  However, IVFx3 is the dominant strategy around 
$2.4M, and if the WTP increases to $3,000,000, then IVFx3 is the dominant strategy 
61.2% of the time.  So, if the goal is to achieve a live birth irrespective of a willingness to 
pay threshold, then IVFx3 would be the preferred strategy.  Figure 8 shows the preferred 
strategy statistics for women aged 40 to 42 with a WTP of $3M and figure 9 represents 
the same data for women over 42.    
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Table 9 
Monte Carlo Simulation Results, Costs per Live birth in 2016 US Dollars ($) 
CER Mean Standard 
Deviation 
90% CI 
Women aged under 
40 
        
   
       IVF-PGS 49,747.62 7,567.13 / .02 35,940.98 – 67,448.21 
       IVFx3 90,218.05 4,131.48 / .01 81,385.64 – 102,082.82 
    
Women aged 40-42 
       
   
      IVF-PGS 93,209.91 3,856.99 / .01 76,264.17 – 115,217.94 
      IVFx3 249,967.25 2,018.23 / .01 225,086.63 – 278,896.11 
    
Women aged over 
42 
   
    
     IVF-PGS 387,430.75 89,660 333,234.11 - 460,074.43 
     IVFx3 754,703.10 87,211 676,497.64 - 850,820.67 
 
Note. Standard deviation depicted as standard deviation of costs / standard deviation of 
effectiveness. 
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Figure 7.  Preferred strategy at a WTP of $3M for women aged under 40.   
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Figure 8.  Preferred strategy at a WTP of $3M for women aged 40-42 
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Figure 9.  Preferred strategy at a WTP of $3M for women over 42.   
 
Summary 
Data was collected from the literature, public sources, and one private clinic.  The 
data collected was costs and clinical probabilities for the cost-effectiveness model.  The 
research questions were whether there were statistical differences in cost-effectiveness 
between strategies of one cycle of IVF with PGS versus three cumulative cycles of IVF 
without PGS, and if there were differences by age group.  The results show negative 
ICERs for all age groups in aggregate, and the age groups of women aged under 40 and 
women aged 40-42.  The results also show that neither strategy was dominant for women 
over 42, with a positive ICER of around $2.4 million.  For both research questions, z-
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scores provided p-values less than .05 based on confidence intervals around the ICERs 
for each age group.  These results confirm that we can reject the null hypothesis and 
accept the alternate hypothesis for both research questions.   
Univariate analysis was performed on a base case of women aged under 40.  All 
costs and clinical probabilities were varied by plus or minus 25%.  The results show that 
clinical probabilities of a live birth for the IVFx3 arm provide the most variability in the 
expected ICER value.  Further, Monte Carlo simulations were performed to determine the 
robustness of the model with Dirichlet distributions used for the clinical probabilities and 
lognormal distributions used for the costs.  For women aged 40-42, no change to the 
dominance of IVF-PGS as a cost-effective option was observed, regardless of 
willingness-to-pay.  However, for women aged under 40 and women over 42 age group, 
IVF-PGS was not always dominant and was not the preferred strategy when there were 
no willingness-to-pay limits.  
I will discuss these results in more detail in Chapter 5.  The interpretation of the 
results will be discussed and the social change implications will be discussed.  Further, 
the limitations of the study and recommendations for future research will be examined.  
Lastly, the study will be summarized and concluded.       
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
In this study, I examined a cost-effectiveness model where two strategies were 
compared to determine the most cost-effective intervention to achieve a live birth.  The 
two strategies were IVF in one cycle paired with PGS and IVF three consecutive times 
without PGS.  I examined three different age groups: Women aged under 40, women 
aged 40-42, and women aged over 42.   
The results show that IVF with PGS was the dominant strategy for women aged 
under 40 and women aged 40-42.  However, the ICER for women aged over 42 was 
positive, although no dominant strategy could be determined.  Further, univariate analysis 
of the base case of women aged under 40 showed that varying the clinical probability of 
live birth in the IVFx3 arm had the most impact to the expected value.   
Lastly, PSA and Monte Carlo simulation showed that the findings were consistent 
across age groups.  For women aged under 40 and aged 40-42, IVF paired with PGS was 
the dominant strategy at any willingness-to-pay (WTP) threshold.  However, for women 
aged over 42, IVF with PGS was preferred at a lower WTP, but IVF performed three 
times consecutively was preferred at higher price points to achieve a live birth.  
This chapter will include interpretation of these results along with the 
implications for clinical application and society in general.  I will also discuss the 
limitations of the study and make recommendations for future research.   
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Interpretation of the Findings 
 The results of the study returned a statistical difference between strategies for 
cost-effectiveness and also showed differences between age groups.  PGS paired with 
IVF alone is definitively more cost-effective than three consecutive cycles of IVF for 
women aged 40-42 and in the vast majority of cases for women aged under 40.  For 
women aged over 42, no strategy was dominant and many factors could come into play to 
determine the best course of clinical action, including factors that go into the protection 
motivation theory. 
Looking first at the ICERs, the results showed that for women aged under 40 and 
aged 40-42, cost per live birth was much less for IVF with PGS, and the effectiveness 
was better than with IVF alone performed three times consecutively.  For women aged 
over 42, no strategy was dominant as the IVFx3 arm was more effective but more costly 
in achieving a live birth.  This is consistent with some recent studies on CEA in IVF and 
PGS, where PGS is seen as cost-effective for younger women but not in higher age 
groups (Hodes-Wertz et al., 2015).   
 The results of this study point clearly to the clinical probability of the 
interventions as having the most impact on cost-effectiveness.  Looking at the literature, 
in many studies where PGS was not cost-effective, researchers used a much lower 
clinical probability for PGS with IVF than the alternate intervention.  For example, 
Mersereau et al. (2008) concluded that for women aged under 40, PGS was less cost 
effective than IVF with PGS in just one cycle, but that for women aged over 40, the cost-
effectiveness was the same.  Those findings were made prior to the advent of new PGS 
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technologies (PGS#2).  Further, the clinical probability of PGS in the IVF-PGS arm of 
that study was 21.7% for both women aged under 40 and women aged over 40, where the 
IVF alone live birth rates were 37.8% and 20.7%, respectively. The IVF-PGS arm of our 
study for women aged under 40 was 63% based on the most recent studies using PGS#2 
techniques, but for women aged over 40, it was an average of 20.7% also.  Univariate 
analysis shows that a live birth rate as low as 48% for the IVF-PGS arm of our study 
would move the ICER to positive.   
 Other contrary findings that showed that PGS is not cost-effective in any age 
group used were based on very low clinical probabilities when evaluating PGS.  Kushnir 
et al (2016) used a PGS live birth rate per cycle of 17.7% for women over 37.  By 
comparison, I used a live birth rate of 33.3% for women aged 40-42 in this study.  Our 
results for that age group showed that almost 100% of Monte Carlo simulations that IVF 
paired with PGS were more cost-effective than IVF alone in three cycles.  This finding is 
consistent with specific studies for women aged 40-43.  Lee et al. (2015) observed a live 
birth rate for that age group of 45.5%, much higher than the clinical probability used in 
this study. 
 For women aged under 40, IVF paired with PGS is the most cost-effective 
approach in the majority of cases.  The findings most likely conflate multiple age groups 
under 40 to explain the fact that IVF performed three consecutive times was preferred in 
nearly a quarter of Monte Carlo simulations, as it is clear from almost any study 
involving IVF that the single-most important factor to achieving a live birth is maternal 
age (Sunderam et al., 2015).   
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The result that IVF performed three consecutive times is more costly but more 
effective in achieving a live birth for women aged over 42 complicates the discussion 
about how best to treat these patients.  As discussed previously, IVFx3 was the dominant 
strategy around $2.4M, and if the WTP increases to $3,000,000, then IVFx3 is the 
dominant strategy 61.2% of the time.  Where money is no object, clearly women should 
attempt IVF three times consecutively to achieve a live birth.  Women of a higher 
socioeconomic class, or with higher incomes, may potentially choose to proceed with 
three cycles of IVF because their willingness to pay for a better outcome is higher than 
other women.  Where the patient is the payer, which is usually the case in the United 
States, this result can be linked to higher incomes affecting the overall cost-effectiveness.  
Also, where insurance covers IVF up to that number, for example, but does not cover 
PGS, IVFx3 may be the right approach for this cohort.  This finding is contrary to a 
recent study that showed that PGS#2 was cost-effective across all age groups (Resetkova 
et al., 2013).  However, that study also averaged costs and probabilities across the age 
spectrum, and did not distinguish age groups.   
Researchers in many of the CEA studies to date have compared the same number 
of cycles in each arm, and direct comparisons are difficult to make.  Intuitively, one 
would imagine that performing the same procedure three times compared to that 
procedure paired with screening would obviously be more costly, which was true in all 
three scenarios.  Costs per live birth were far higher for IVFx3 compared to IVF with 
PGS alone.  However, the clinical probabilities of achieving a live birth is what drives the 
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overall analysis, and is what most certainly will drive the debate over the use of PGS in 
routine clinical practice.    
For women over 42, where the cost-effectiveness is not as clear per strategy, other 
factors related to the protection motivation theory could be examined.  These include the 
threat appraisals and coping appraisals of other parts of the IVF process, excluding costs. 
These could be the apprehension of not achieving a live birth, the fear of a prolonged 
timeline, and the emotional toll such a process could have.  While costs and economic 
factors play into the PMT, they are not the only things to consider when determining if a 
measure like genetic screening should be employed (Helmes, 2002). 
As mentioned in Chapter 2, researchers have reported a wide variation of the cost 
per live birth using IVF, anywhere from $19,416 to as high as $291,907, depending on 
age group and PGS status (Chambers et al., 2009; Hodes-Wertz et al., 2015; Resetkova et 
al., 2013).  My study found a one-cycle cost per live birth with PGS to be $48,995.85 for 
women under the age of 40 and $382,653.70 for women over the age of 42.  This is fairly 
consistent with the literature in showing a wide range between age groups, and is 
generally consistent with the costs per live birth based on what costs were included in the 
study. 
Lastly, in this study I attempted to examine a real life dilemma for patients 
attempting to achieve a live birth using IVF.  The choice to employ genetic screening or 
simply stay the course through multiple cycles is a common one for many patients.  I 
employed the most recent findings for cumulative success rates in IVF and for IVF paired 
with PGS, discriminated by age group.  The results highlight the debate around PGS but 
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also advance the body of evidence of PGS as a useful clinical tool in certain clinical 
circumstances.  The findings have both limitations and implications for social change.     
Limitations of the Study 
The study had multiple limitations that could have prevented a more accurate 
picture of the cost-effectiveness of the two interventions studied.  First, the model is 
simply theoretical, and used secondary data sources from the literature and other public 
sources to build a model that explores these interventions.  I believe that the model is 
very representative of the most current costs and probabilities for the United States.  The 
literature I used to populate the probabilities, particularly the Smith et al. (2015) that had 
hundreds of thousands of data points, was well designed and used the most current 
technologies.  Any limitation found in the collection of the data from other sources is 
inherent in the model. Particularly, the fact that collection of the data from Smith et al. 
was done in the United Kingdom, not the United States. All other literature sources were 
from the United States and the CDC data is from the US.  All costs were in 2016 dollars 
and so should not have created any bias.    
 Further, certain assumptions were made to make the model as usable as possible.  
For example, it did not explore the costs associated with multiple births, which is a major 
issue with IVF (Kulkarni et al., 2013).  Comparing the rate at which each arm produced 
multiple gestations and the costs associated with multiples could have changed the 
analysis.  We also assumed that every transfer was a single-embryo transfer, which is not 
the usual routine practice of most fertility physicians today (De Sutter, Gerris, & Dhont, 
2002). 
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Further, the study made certain assumptions about fresh and frozen transfers and 
the use of ICSI, and also included the costs of medications which is typically not seen in 
many of the CEA studies for IVF and PGS (Dahdouh et al., 2015).  We also made 
assumptions for the clinical probabilities for the cumulative IVF group based on certain 
drop-out rates between cycles.   
The study also did not examine any other outcomes of an IVF cycle such ectopic 
pregnancies or elective abortions.  Other assumptions of the model were that every 
woman in every cohort had a euploid embryo after getting PGS, which is not always the 
case, especially in older women (Hodes-Wertz et al., 2012).   
Recommendations 
 Recommendations based on the findings of this study are threefold.  First, a 
prospective, multi-center trial comparing IVF in one cycle with PGS and IVF performed 
three consecutive times should be attempted.  Such a trial should account for all of the 
real world factors and costs associated with a woman’s journey to achieve a live birth, 
and should utilize the most recent technology for PGS (aCGH or NGS).  The study could 
provide insight into PGS live birth rates based on varying age groups and disease states 
and could use real-world costs to determine cost-effectiveness (Orvieto, 2016). 
 Second, clinical societies such as the ASRM and ACOG that govern IVF should 
examine this study and others on the topic of PGS and make firm guideline 
recommendations based on multiple factors, including cost-effectiveness.  The most 
recent guidelines from the ACOG are almost 9 years old now and do not reflect the 
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current technologies for PGS or the studies that examine the clinical efficacy and cost-
effectiveness (“ACOG Committee Opinion No. 430,” 2009).   
 Lastly, I recommend further studies into the economic impact of PGS and new 
genetic screening techniques on the health care system at large.  One such study could be 
a cost-benefit analysis of how PGS impacts society at large and the overall economic 
impact of delivering healthy, single infants as a result of IVF.  One impact of PGS not 
examined in this study is the prevalence of healthy infants without genetic defects.  
Children born with a genetic birth defect in the US cost the healthcare system over $23 
Billion every year (Arth, 2017).  New genetic screening tests could impact the economics 
of health care in general, but require more research to fully understand the effect.      
Implications 
 The study has significant social implications based on the results, especially in the 
United States where the vast majority of patients pay their own way to get assistance in 
achieving a live birth.  Many clinics in the United States have moved to novel payment 
techniques to keep patients in IVF longer, including guarantees on a live birth and one 
price for three consecutive cycles of IVF (Cha, 2017).  Cost-effectiveness tools can help 
these parents and other stakeholders to make the best clinical decisions based on limited 
resources.  The implications for social change mainly affect four different groups, 
discussed in order: patients, physicians (RE), insurers, and policy-makers. 
 For patients, having as much information as possible prior to pursuing IVF or 
ART is critical, especially given the competitive nature of many IVF clinics.  
Organizations such as Resolve (resolve.org) seek to help infertile women understand 
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pregnancy rates and live birth rates between different clinics. The CDC publishes data 
every year and seeks to educate patients about what clinics have the highest success rates 
and what those rates mean (Centers for Disease Control and Prevention, 2016).  Genetic 
screening is a particularly difficult topic to understand for most patients and the onus of 
explaining such a difficult concept falls to the physician, or in some cases, genetic 
counselor (Hamilton et al., 2014).  However, often times costs associated with genetic 
screening and the outcomes are not clearly articulated.  The results of this study can help 
patients understand their options, particularly if costs are not an issue in situations where 
IVF is covered but PGS is not (Schwartz et al., 2017).   
 As discussed, reproductive endocrinologists are often the gatekeeper to genetic 
testing in the IVF clinic.  They typically have the most information about the options 
available to a patient undergoing IVF.  Understanding not only what the most recent 
literature says about the clinical efficacy of PGS but the cost-effectiveness by age group 
will enable physicians to educate their patients about the best options for them.  Other 
factors associated with each intervention should also be factored into a decision that is 
ultimately made by the patient about their own treatment.  This study helps to add to the 
available literature on PGS and can help inform practice guidelines or future research.   
 Insurance companies to date still do not cover IVF or PGS in the vast majority of 
states (Boulet et al., 2015).  Many employers may seek to provide such coverage for their 
employees as an added benefit, and some insurance companies may provide it at a higher 
premium (Collura & Adamson, 2017).  CEAs such as this one could inform financial 
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decision-making in order to best cover these patients and possibly add new patients under 
coverage. 
 A final implication of the results of the study are around the univariate analysis 
that indicates that the clinical probabilities are the key to cost-effectiveness of these 
interventions, particularly in later cycles of IVF.  If IVF progressed to show improved 
clinical probabilities in the second and third cycles without PGS, the cost-effectiveness 
models would change greatly.  Other techniques involved with IVF should be considered 
to improve those probabilities to impact the cost-effectiveness relationship between 
interventions. This also implies that further research needs to constantly take into account 
the most recent techniques involved with IVF in general, including vitrification, 
transferals, and IVF techniques. 
Conclusion 
 Society has a vested interest in understanding the cost-effectiveness of different 
clinical interventions to achieve certain health benefits or outcomes.  For assisted 
reproductive techniques, the technology involved is rapidly evolving and determining the 
best clinical interventions to achieve a live birth is difficult from the perspective of the 
patient. New technology can be useful in achieving the desired outcome but can be 
controversial as to whether it should be implemented in routine clinical practice.  The 
cost-effectiveness of these interventions is one key factor that clinicians and patients 
should take into consideration as part of their decision-making. 
This study sought to understand the cost-effectiveness of two different 
interventions used in the field of IVF. The first was using the controversial genetic 
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screening technique PGS in one cycle of IVF.  The second intervention was in pursuing 
IVF without PGS in three consecutive cycles. These two interventions had never been 
compared for cost-effectiveness before and therefore the study was novel.  The research 
questions asked were whether there was a cost-effectiveness difference between the 
interventions and in three different age groups.   
 Looking at the incremental cost-effectiveness ratios yielded results that allowed 
us to reject the null hypothesis for both research questions.  For women aged under 40 
years old, IVF paired with PGS was less expensive and more effective than the IVFx3 
intervention.  However in Monte Carlo simulations, the preferred method depended on 
the willingness-to-pay ratio.  For women aged 40-42, IVF with PGS was the dominant 
strategy in all scenarios.  Lastly, for women aged over 42, no strategy was dominant and 
if the willingness-to-pay was sufficiently high enough, IVF three consecutive times 
would be the preferred choice.   
 Univariate analysis showed that the key factor was in the clinical probabilities, 
particularly in the rounds 2 and 3 of IVF for the IVFx3 arm.  This is consistent with a 
review of the literature, where past studies used a much lower clinical probability for a 
live birth when using PGS.  Those studies mainly were based on PGS#1 technologies and 
did not reflect current clinical results.   
 The implications of the study are important for social change.  IVF is a $16B 
industry in the United States, mainly funded out-of-pocket by patients.  Understanding 
the cost-effectiveness of these interventions will make patients, clinicians, payers, and 
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policymakers more informed about the right clinical decisions to make to save the most 
money.   
 Further research is required to understand all of the real world costs involved with 
these interventions, some of which were ignored or assumed to be nominal.  Other studies 
examining the overall economic impact of PGS should also be considered.  Lastly, this 
study can help governing bodies to provide guidelines to clinicians when new technology 
is introduced into clinical practice.   
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Appendix A: List of Acronyms 
aCGH / CGH – Array Comparative Genomic Hybridization 
ART - Assisted Reproductive Technology 
CCS - Comprehensive Chromosomal Screening  
CDC - Centers for Disease Control 
CEA – Cost-effectiveness Analysis 
CER – Cost-Effectiveness Ratio 
CMS – Center For Medicaid and Medicare Services 
eSET – Elective Single embryo Transfer 
ET – Embryo Transfer 
FET – Frozen Embryo Transfer 
FISH – Fluorescence In-Situ Hybridization 
FT – Fresh Embryo Transfer 
HIPAA – Health Information Portability and Accountability Act 
ICER – Incremental Cost-effectiveness Ratio 
ICSI – Intracytoplasmic sperm injection 
IVF – In Vitro Fertilization 
NGS – Next Generation Sequencing 
OB/GYN – Obstetrician / Gynecologist 
PCR – Polymerase Chain Reaction 
PGD – Preimplantation Genetic Diagnosis 
PHI – Personal Health Information 
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PGS – Preimplantation Genetic Screening 
PSA – Probabilistic Sensitivity Analysis 
RE / REI – Reproductive Endocrinology / Infertility 
RCT – Randomized Controlled Trials 
RPL – Recurrent Pregnancy Loss 
SART – Society for Assisted Reproductive Technology 
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